Non-serious adverse events
|
12-Month Double-blind Period: Placebo |
12-Month Double-blind Period: Romosozumab |
36-Month Study Period: Placebo/Denosumab |
36-Month Study Period: Romosozumab/Denosumab |
Total subjects affected by non serious adverse events
|
|
|
|
|
subjects affected / exposed
|
2823 / 3576 (78.94%) |
2773 / 3581 (77.44%) |
3130 / 3576 (87.53%) |
3112 / 3581 (86.90%) |
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
|
|
|
Acrochordon
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
occurrences all number
|
3 |
0 |
4 |
0 |
Adenocarcinoma gastric
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Adenoma benign
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Adrenal neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Angiomyolipoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Anogenital warts
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Basal cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
6 / 3581 (0.17%) |
17 / 3576 (0.48%) |
18 / 3581 (0.50%) |
occurrences all number
|
12 |
7 |
19 |
21 |
Benign bone neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Benign breast neoplasm
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
4 |
1 |
Benign gastric neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Benign lung neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
3 |
1 |
Benign neoplasm
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Benign neoplasm of adrenal gland
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Benign neoplasm of bladder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Benign neoplasm of cornea
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Benign neoplasm of skin
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
1 |
4 |
4 |
Benign neoplasm of thyroid gland
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
7 / 3581 (0.20%) |
13 / 3576 (0.36%) |
17 / 3581 (0.47%) |
occurrences all number
|
9 |
7 |
14 |
17 |
Benign ovarian tumour
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Benign pancreatic neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Benign pleural neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Benign renal neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Benign salivary gland neoplasm
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Benign soft tissue neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Bowen's disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
3 |
0 |
3 |
Breast cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Breast fibroma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Cancer pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Chronic lymphocytic leukaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Colon adenoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
3 |
2 |
5 |
Colon cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Ear neoplasm
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Enchondromatosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Eye naevus
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Fibroadenoma of breast
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Fibroma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
4 |
1 |
Fibromatosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Fibrous histiocytoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Gastric neoplasm
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Gastrointestinal tract adenoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Haemangioma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
4 |
0 |
Haemangioma of bone
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Haemangioma of liver
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
2 |
3 |
Haemangioma of skin
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hair follicle tumour benign
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Hepatic neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Intraductal papilloma of breast
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Invasive ductal breast carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Juvenile melanoma benign
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Keratoacanthoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Kidney angiomyolipoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Leiomyoma
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
5 |
2 |
Lipofibroma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Lipoma
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
6 / 3581 (0.17%) |
6 / 3576 (0.17%) |
8 / 3581 (0.22%) |
occurrences all number
|
2 |
6 |
6 |
8 |
Lymphoproliferative disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Malignant melanoma in situ
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Melanocytic naevus
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
1 |
5 |
4 |
Meningioma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Meningioma benign
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Metastases to lung
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Metastases to peritoneum
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Non-Hodgkin's lymphoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Oral haemangioma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Ovarian cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Papillary thyroid cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Polycythaemia vera
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Pyogenic granuloma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Renal neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Seborrhoeic keratosis
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
6 / 3581 (0.17%) |
9 / 3576 (0.25%) |
12 / 3581 (0.34%) |
occurrences all number
|
6 |
7 |
10 |
13 |
Skin cancer
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Skin papilloma
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
6 / 3581 (0.17%) |
3 / 3576 (0.08%) |
9 / 3581 (0.25%) |
occurrences all number
|
2 |
6 |
3 |
10 |
Squamous cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Squamous cell carcinoma of skin
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
3 |
1 |
4 |
Sweat gland tumour
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Thyroid adenoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Thyroid neoplasm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Transitional cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Uterine leiomyoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
4 / 3581 (0.11%) |
3 / 3576 (0.08%) |
7 / 3581 (0.20%) |
occurrences all number
|
0 |
4 |
3 |
7 |
Vascular disorders
|
|
|
|
|
Aneurysm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Angiosclerosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Aortic aneurysm
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
2 |
5 |
4 |
Aortic arteriosclerosis
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
11 / 3581 (0.31%) |
30 / 3576 (0.84%) |
21 / 3581 (0.59%) |
occurrences all number
|
6 |
12 |
30 |
22 |
Aortic calcification
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
3 |
0 |
Aortic dilatation
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
5 |
3 |
Aortic dissection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Aortic elongation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Aortic stenosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
occurrences all number
|
1 |
0 |
4 |
5 |
Aortic thrombosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Arterial disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Arterial occlusive disease
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
2 |
2 |
Arterial stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Arteriosclerosis
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
15 / 3581 (0.42%) |
33 / 3576 (0.92%) |
30 / 3581 (0.84%) |
occurrences all number
|
15 |
16 |
35 |
31 |
Blood pressure fluctuation
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
5 |
1 |
5 |
5 |
Blood pressure inadequately controlled
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Capillary fragility
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Capillary leak syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Deep vein thrombosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
0 |
3 |
2 |
Diastolic hypotension
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Embolism
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Embolism arterial
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Essential hypertension
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
6 / 3576 (0.17%) |
5 / 3581 (0.14%) |
occurrences all number
|
4 |
4 |
6 |
5 |
Extravasation blood
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Flushing
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
3 |
2 |
3 |
Haematoma
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
20 / 3581 (0.56%) |
27 / 3576 (0.76%) |
40 / 3581 (1.12%) |
occurrences all number
|
25 |
23 |
32 |
44 |
Haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hot flush
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
11 / 3581 (0.31%) |
12 / 3576 (0.34%) |
13 / 3581 (0.36%) |
occurrences all number
|
13 |
12 |
13 |
14 |
Hyperaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hypertension
|
|
|
|
|
subjects affected / exposed
|
260 / 3576 (7.27%) |
219 / 3581 (6.12%) |
411 / 3576 (11.49%) |
384 / 3581 (10.72%) |
occurrences all number
|
274 |
244 |
461 |
441 |
Hypertensive angiopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Hypertensive crisis
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
12 / 3581 (0.34%) |
16 / 3576 (0.45%) |
21 / 3581 (0.59%) |
occurrences all number
|
8 |
13 |
17 |
24 |
Hypertensive emergency
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
3 |
1 |
Hypotension
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
7 / 3581 (0.20%) |
24 / 3576 (0.67%) |
17 / 3581 (0.47%) |
occurrences all number
|
21 |
7 |
27 |
17 |
Hypovolaemic shock
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Intermittent claudication
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
3 |
3 |
3 |
Ischaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Labile blood pressure
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Lymphoedema
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
2 |
1 |
Lymphostasis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Microangiopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Orthostatic hypertension
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Orthostatic hypotension
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Peripheral arterial occlusive disease
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
8 / 3581 (0.22%) |
9 / 3576 (0.25%) |
15 / 3581 (0.42%) |
occurrences all number
|
6 |
8 |
11 |
15 |
Peripheral artery occlusion
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
3 |
3 |
Peripheral artery stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Peripheral artery thrombosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Peripheral circulatory failure
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Peripheral coldness
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Peripheral embolism
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Peripheral ischaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Peripheral vascular disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
5 / 3576 (0.14%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
5 |
0 |
Peripheral venous disease
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
19 / 3581 (0.53%) |
26 / 3576 (0.73%) |
32 / 3581 (0.89%) |
occurrences all number
|
15 |
21 |
27 |
34 |
Phlebitis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
6 / 3576 (0.17%) |
9 / 3581 (0.25%) |
occurrences all number
|
2 |
3 |
6 |
10 |
Phlebitis superficial
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
3 |
3 |
4 |
Phlebolith
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Poor peripheral circulation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Post thrombotic syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Raynaud's phenomenon
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
1 |
4 |
3 |
Shock
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Spider vein
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Subgaleal haematoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Superior vena cava syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Temporal arteritis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Thrombophlebitis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
7 / 3576 (0.20%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
3 |
7 |
5 |
Thrombophlebitis superficial
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
2 |
6 |
3 |
Thrombosed varicose vein
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Thrombosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
3 |
0 |
Varicophlebitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Varicose ulceration
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
2 / 3581 (0.06%) |
9 / 3576 (0.25%) |
7 / 3581 (0.20%) |
occurrences all number
|
8 |
2 |
10 |
8 |
Varicose vein
|
|
|
|
|
subjects affected / exposed
|
25 / 3576 (0.70%) |
17 / 3581 (0.47%) |
46 / 3576 (1.29%) |
39 / 3581 (1.09%) |
occurrences all number
|
26 |
17 |
50 |
40 |
Varicose vein ruptured
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Vascular calcification
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Vascular fragility
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Vascular insufficiency
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
2 |
1 |
Vascular pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Vascular rupture
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Vasculitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
1 |
2 |
Vasodilatation
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
3 |
0 |
3 |
0 |
Vein disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Venous thrombosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Venous thrombosis limb
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
1 |
2 |
4 |
Withdrawal hypertension
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Surgical and medical procedures
|
|
|
|
|
Abdominal hernia repair
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Artificial crown procedure
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Bladder repair
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Bunion operation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Cancer surgery
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Cataract operation
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
8 / 3581 (0.22%) |
occurrences all number
|
2 |
2 |
4 |
9 |
Colectomy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Colostomy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Corneal transplant
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Cyst removal
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Dental care
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Dental cleaning
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Dental prosthesis placement
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Dermatofibroma removal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Endodontic procedure
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Eye operation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Hip arthroplasty
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Hypotensive anaesthesia procedure
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Inguinal hernia repair
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Intervertebral disc operation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Intraocular lens implant
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Large intestinal polypectomy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Lip operation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Nail operation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Peripheral nerve operation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Plastic surgery to the face
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Rotator cuff repair
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Skin neoplasm excision
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
3 |
Spinal fusion surgery
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Suture insertion
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Thyroidectomy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Toe operation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Tooth extraction
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
8 / 3581 (0.22%) |
15 / 3576 (0.42%) |
22 / 3581 (0.61%) |
occurrences all number
|
4 |
9 |
16 |
23 |
Wisdom teeth removal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
General disorders and administration site conditions
|
|
|
|
|
Administration site erythema
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
3 |
0 |
3 |
Administration site pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Administration site reaction
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Adverse drug reaction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
2 |
1 |
Application site bruise
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Application site dermatitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Application site eczema
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Application site pruritus
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Application site rash
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Asthenia
|
|
|
|
|
subjects affected / exposed
|
79 / 3576 (2.21%) |
84 / 3581 (2.35%) |
111 / 3576 (3.10%) |
117 / 3581 (3.27%) |
occurrences all number
|
94 |
97 |
135 |
140 |
Axillary pain
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Calcinosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Catheter site haematoma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Catheter site pain
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Chest discomfort
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
6 / 3581 (0.17%) |
6 / 3576 (0.17%) |
8 / 3581 (0.22%) |
occurrences all number
|
3 |
6 |
7 |
9 |
Chest pain
|
|
|
|
|
subjects affected / exposed
|
30 / 3576 (0.84%) |
30 / 3581 (0.84%) |
44 / 3576 (1.23%) |
39 / 3581 (1.09%) |
occurrences all number
|
30 |
31 |
44 |
40 |
Chills
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
occurrences all number
|
3 |
3 |
4 |
5 |
Crying
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Cyst
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
7 / 3581 (0.20%) |
7 / 3576 (0.20%) |
12 / 3581 (0.34%) |
occurrences all number
|
4 |
7 |
7 |
12 |
Discomfort
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
3 |
3 |
Drug intolerance
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
10 / 3581 (0.28%) |
12 / 3576 (0.34%) |
14 / 3581 (0.39%) |
occurrences all number
|
7 |
10 |
12 |
14 |
Exercise tolerance decreased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
4 |
3 |
Face oedema
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
6 / 3576 (0.17%) |
5 / 3581 (0.14%) |
occurrences all number
|
4 |
5 |
6 |
5 |
Facial pain
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
4 / 3581 (0.11%) |
11 / 3576 (0.31%) |
7 / 3581 (0.20%) |
occurrences all number
|
7 |
4 |
12 |
8 |
Fat tissue increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Fatigue
|
|
|
|
|
subjects affected / exposed
|
52 / 3576 (1.45%) |
48 / 3581 (1.34%) |
61 / 3576 (1.71%) |
61 / 3581 (1.70%) |
occurrences all number
|
59 |
56 |
70 |
71 |
Feeling abnormal
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Feeling cold
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Feeling hot
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
8 / 3581 (0.22%) |
4 / 3576 (0.11%) |
9 / 3581 (0.25%) |
occurrences all number
|
2 |
10 |
4 |
11 |
Feeling of body temperature change
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Gait disturbance
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
8 / 3576 (0.22%) |
9 / 3581 (0.25%) |
occurrences all number
|
4 |
6 |
8 |
11 |
General physical health deterioration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Generalised oedema
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
2 |
3 |
4 |
Granuloma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Impaired healing
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
3 |
1 |
Implant site cyst
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Implant site haematoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Implant site pain
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Inflammation
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
1 |
3 |
2 |
Influenza like illness
|
|
|
|
|
subjects affected / exposed
|
39 / 3576 (1.09%) |
29 / 3581 (0.81%) |
54 / 3576 (1.51%) |
46 / 3581 (1.28%) |
occurrences all number
|
43 |
30 |
62 |
50 |
Infusion site bruising
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Infusion site extravasation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Injection site bruising
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
29 / 3581 (0.81%) |
21 / 3576 (0.59%) |
29 / 3581 (0.81%) |
occurrences all number
|
24 |
32 |
25 |
32 |
Injection site cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Injection site dermatitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Injection site erythema
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
54 / 3581 (1.51%) |
5 / 3576 (0.14%) |
56 / 3581 (1.56%) |
occurrences all number
|
5 |
110 |
5 |
113 |
Injection site haematoma
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
8 / 3581 (0.22%) |
6 / 3576 (0.17%) |
8 / 3581 (0.22%) |
occurrences all number
|
6 |
9 |
6 |
9 |
Injection site haemorrhage
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
13 / 3581 (0.36%) |
14 / 3576 (0.39%) |
13 / 3581 (0.36%) |
occurrences all number
|
15 |
13 |
16 |
13 |
Injection site hypersensitivity
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
8 |
1 |
8 |
Injection site induration
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
5 |
1 |
5 |
Injection site inflammation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
1 |
3 |
Injection site mass
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Injection site nodule
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Injection site oedema
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
3 |
1 |
3 |
Injection site pain
|
|
|
|
|
subjects affected / exposed
|
46 / 3576 (1.29%) |
62 / 3581 (1.73%) |
47 / 3576 (1.31%) |
63 / 3581 (1.76%) |
occurrences all number
|
75 |
92 |
76 |
94 |
Injection site papule
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Injection site paraesthesia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
10 |
1 |
10 |
1 |
Injection site pruritus
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
27 / 3581 (0.75%) |
7 / 3576 (0.20%) |
28 / 3581 (0.78%) |
occurrences all number
|
8 |
51 |
8 |
52 |
Injection site rash
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
13 / 3581 (0.36%) |
2 / 3576 (0.06%) |
13 / 3581 (0.36%) |
occurrences all number
|
3 |
23 |
3 |
23 |
Injection site reaction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
5 / 3581 (0.14%) |
1 / 3576 (0.03%) |
5 / 3581 (0.14%) |
occurrences all number
|
1 |
5 |
1 |
5 |
Injection site swelling
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
16 / 3581 (0.45%) |
1 / 3576 (0.03%) |
16 / 3581 (0.45%) |
occurrences all number
|
1 |
36 |
1 |
37 |
Injection site urticaria
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
8 |
1 |
8 |
Injection site warmth
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
3 |
0 |
3 |
Injury associated with device
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Ischaemic ulcer
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Local swelling
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Localised oedema
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
0 |
2 |
1 |
Malaise
|
|
|
|
|
subjects affected / exposed
|
18 / 3576 (0.50%) |
17 / 3581 (0.47%) |
29 / 3576 (0.81%) |
22 / 3581 (0.61%) |
occurrences all number
|
20 |
20 |
32 |
25 |
Mass
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
0 |
2 |
2 |
Medical device pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Mucosal dryness
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Mucosal inflammation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Nodule
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
occurrences all number
|
4 |
1 |
4 |
3 |
Non-cardiac chest pain
|
|
|
|
|
subjects affected / exposed
|
23 / 3576 (0.64%) |
26 / 3581 (0.73%) |
42 / 3576 (1.17%) |
36 / 3581 (1.01%) |
occurrences all number
|
23 |
27 |
47 |
38 |
Oedema
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
2 |
2 |
Oedema peripheral
|
|
|
|
|
subjects affected / exposed
|
67 / 3576 (1.87%) |
86 / 3581 (2.40%) |
97 / 3576 (2.71%) |
127 / 3581 (3.55%) |
occurrences all number
|
74 |
96 |
114 |
139 |
Pain
|
|
|
|
|
subjects affected / exposed
|
40 / 3576 (1.12%) |
39 / 3581 (1.09%) |
56 / 3576 (1.57%) |
45 / 3581 (1.26%) |
occurrences all number
|
42 |
42 |
59 |
49 |
Pelvic mass
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Peripheral swelling
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
20 / 3581 (0.56%) |
30 / 3576 (0.84%) |
34 / 3581 (0.95%) |
occurrences all number
|
22 |
23 |
32 |
40 |
Polyp
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Puncture site haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Puncture site oedema
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Puncture site pain
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
2 |
2 |
Puncture site reaction
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Pyrexia
|
|
|
|
|
subjects affected / exposed
|
66 / 3576 (1.85%) |
49 / 3581 (1.37%) |
74 / 3576 (2.07%) |
58 / 3581 (1.62%) |
occurrences all number
|
79 |
61 |
88 |
70 |
Sensation of foreign body
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Sense of oppression
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
3 |
0 |
3 |
Soft tissue inflammation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Suprapubic pain
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Swelling
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
2 |
1 |
Temperature intolerance
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Thirst
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
0 |
3 |
1 |
Ulcer haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Vaccination site bruising
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Vaccination site induration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Vaccination site pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Vessel puncture site bruise
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
occurrences all number
|
4 |
4 |
4 |
5 |
Vessel puncture site erythema
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Vessel puncture site haematoma
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
0 |
3 |
1 |
Vessel puncture site haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Vessel puncture site pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Vessel puncture site reaction
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Xerosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
2 |
1 |
Immune system disorders
|
|
|
|
|
Allergic oedema
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
4 |
1 |
Allergy to animal
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Allergy to arthropod bite
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
2 |
2 |
Allergy to arthropod sting
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
2 |
1 |
Allergy to chemicals
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Allergy to plants
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Allergy to vaccine
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Atopy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Contrast media allergy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Drug hypersensitivity
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
14 / 3576 (0.39%) |
15 / 3581 (0.42%) |
occurrences all number
|
5 |
3 |
14 |
18 |
Food allergy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
occurrences all number
|
0 |
3 |
2 |
5 |
Hypersensitivity
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
10 / 3576 (0.28%) |
7 / 3581 (0.20%) |
occurrences all number
|
4 |
5 |
10 |
7 |
Mite allergy
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Multiple allergies
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Rubber sensitivity
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Seasonal allergy
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
6 / 3581 (0.17%) |
18 / 3576 (0.50%) |
15 / 3581 (0.42%) |
occurrences all number
|
9 |
6 |
19 |
15 |
Transplant rejection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Type I hypersensitivity
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Social circumstances
|
|
|
|
|
Bereavement
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Dental prosthesis user
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Family stress
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Immobile
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Menopause
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Stress at work
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Reproductive system and breast disorders
|
|
|
|
|
Adenomyosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Anisomastia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Atrophic vulvovaginitis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
4 / 3576 (0.11%) |
6 / 3581 (0.17%) |
occurrences all number
|
2 |
4 |
4 |
6 |
Breast calcifications
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Breast cyst
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
5 / 3576 (0.14%) |
6 / 3581 (0.17%) |
occurrences all number
|
3 |
3 |
5 |
6 |
Breast discharge
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Breast disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Breast engorgement
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Breast enlargement
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Breast haematoma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Breast mass
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
7 / 3576 (0.20%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
2 |
7 |
4 |
Breast pain
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
8 / 3581 (0.22%) |
12 / 3576 (0.34%) |
12 / 3581 (0.34%) |
occurrences all number
|
7 |
9 |
12 |
13 |
Breast swelling
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Breast ulceration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Cervical dysplasia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Cervical polyp
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Cervix inflammation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Colpocele
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Cystocele
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
9 / 3576 (0.25%) |
7 / 3581 (0.20%) |
occurrences all number
|
4 |
3 |
9 |
7 |
Dysfunctional uterine bleeding
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
4 |
1 |
4 |
4 |
Endometrial hyperplasia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
4 |
0 |
Endometrial hypoplasia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Endometrial thickening
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Fibrocystic breast disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Genital atrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Genital haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Genital labial adhesions
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Genital prolapse
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
occurrences all number
|
3 |
1 |
4 |
3 |
Genital rash
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hydrometra
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hysterocele
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Mammary duct ectasia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Menopausal symptoms
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Ovarian cyst
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
8 / 3576 (0.22%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
2 |
8 |
5 |
Pelvic floor muscle weakness
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Pelvic haematoma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Pelvic pain
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
occurrences all number
|
3 |
2 |
5 |
3 |
Perineal pain
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Postmenopausal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
2 |
5 |
4 |
Pruritus genital
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Rectocele
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
2 |
1 |
Urogenital prolapse
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Uterine disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Uterine haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Uterine mass
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Uterine polyp
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
0 |
2 |
4 |
Uterine prolapse
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
occurrences all number
|
3 |
2 |
6 |
3 |
Uterovaginal prolapse
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Vaginal discharge
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
2 |
3 |
Vaginal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
3 / 3581 (0.08%) |
8 / 3576 (0.22%) |
3 / 3581 (0.08%) |
occurrences all number
|
12 |
3 |
12 |
4 |
Vaginal polyp
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Vaginal prolapse
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
3 |
2 |
Varicocele
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Vulva cyst
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Vulval leukoplakia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Vulvovaginal dryness
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
6 / 3576 (0.17%) |
4 / 3581 (0.11%) |
occurrences all number
|
4 |
3 |
6 |
4 |
Vulvovaginal pruritus
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
6 / 3581 (0.17%) |
occurrences all number
|
7 |
4 |
9 |
6 |
Respiratory, thoracic and mediastinal disorders
|
|
|
|
|
Acute pulmonary oedema
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Acute respiratory distress syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Allergic bronchitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
3 |
1 |
4 |
Allergic cough
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
occurrences all number
|
4 |
2 |
5 |
4 |
Allergic respiratory symptom
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Allergic sinusitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Asthma
|
|
|
|
|
subjects affected / exposed
|
15 / 3576 (0.42%) |
22 / 3581 (0.61%) |
29 / 3576 (0.81%) |
39 / 3581 (1.09%) |
occurrences all number
|
17 |
29 |
33 |
52 |
Asthmatic crisis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Atelectasis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
2 |
5 |
4 |
Bronchial hyperreactivity
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
2 |
3 |
Bronchial obstruction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Bronchiectasis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
11 / 3576 (0.31%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
3 |
11 |
5 |
Bronchitis chronic
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
11 / 3581 (0.31%) |
15 / 3576 (0.42%) |
16 / 3581 (0.45%) |
occurrences all number
|
7 |
12 |
17 |
19 |
Bronchospasm
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
9 / 3576 (0.25%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
9 |
3 |
Catarrh
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
3 / 3581 (0.08%) |
13 / 3576 (0.36%) |
5 / 3581 (0.14%) |
occurrences all number
|
8 |
3 |
15 |
6 |
Chronic obstructive pulmonary disease
|
|
|
|
|
subjects affected / exposed
|
35 / 3576 (0.98%) |
29 / 3581 (0.81%) |
60 / 3576 (1.68%) |
51 / 3581 (1.42%) |
occurrences all number
|
40 |
38 |
85 |
68 |
Chronic respiratory failure
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Cough
|
|
|
|
|
subjects affected / exposed
|
117 / 3576 (3.27%) |
130 / 3581 (3.63%) |
179 / 3576 (5.01%) |
189 / 3581 (5.28%) |
occurrences all number
|
128 |
140 |
202 |
217 |
Diaphragmatic abnormal relaxation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Diaphragmatic disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Dry throat
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
3 |
0 |
Dysphonia
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
12 / 3581 (0.34%) |
10 / 3576 (0.28%) |
22 / 3581 (0.61%) |
occurrences all number
|
10 |
12 |
11 |
22 |
Dyspnoea
|
|
|
|
|
subjects affected / exposed
|
23 / 3576 (0.64%) |
33 / 3581 (0.92%) |
36 / 3576 (1.01%) |
50 / 3581 (1.40%) |
occurrences all number
|
24 |
35 |
39 |
53 |
Dyspnoea exertional
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
9 / 3581 (0.25%) |
12 / 3576 (0.34%) |
13 / 3581 (0.36%) |
occurrences all number
|
9 |
10 |
12 |
14 |
Emphysema
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
7 / 3576 (0.20%) |
11 / 3581 (0.31%) |
occurrences all number
|
1 |
4 |
7 |
12 |
Epistaxis
|
|
|
|
|
subjects affected / exposed
|
19 / 3576 (0.53%) |
24 / 3581 (0.67%) |
26 / 3576 (0.73%) |
35 / 3581 (0.98%) |
occurrences all number
|
22 |
29 |
35 |
41 |
Haemoptysis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
1 |
3 |
3 |
Haemothorax
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Hiccups
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Hydrothorax
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Hypoventilation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hypoxia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
3 |
2 |
Increased bronchial secretion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Increased upper airway secretion
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Interstitial lung disease
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
2 |
3 |
Laryngeal disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
1 |
3 |
1 |
Laryngeal inflammation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Laryngitis allergic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Larynx irritation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Lower respiratory tract inflammation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Lung consolidation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Lung cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Lung disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
0 |
4 |
2 |
Lung infiltration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Mediastinal disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Mouth breathing
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Nasal congestion
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
4 / 3581 (0.11%) |
occurrences all number
|
6 |
4 |
9 |
6 |
Nasal discomfort
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Nasal dryness
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Nasal inflammation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Nasal mucosal disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Nasal mucosal hypertrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Nasal obstruction
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Nasal oedema
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Nasal polyps
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
2 |
1 |
Nasal pruritus
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Nasal septum deviation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
0 / 3576 (0.00%) |
5 / 3581 (0.14%) |
occurrences all number
|
0 |
3 |
0 |
5 |
Nasal septum perforation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Nasal turbinate hypertrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Obstructive airways disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
3 |
2 |
Oropharyngeal discomfort
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Oropharyngeal pain
|
|
|
|
|
subjects affected / exposed
|
26 / 3576 (0.73%) |
26 / 3581 (0.73%) |
35 / 3576 (0.98%) |
39 / 3581 (1.09%) |
occurrences all number
|
27 |
30 |
36 |
44 |
Orthopnoea
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Pharyngeal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Pharyngeal inflammation
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
occurrences all number
|
6 |
3 |
6 |
3 |
Pleural disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Pleural effusion
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
6 / 3576 (0.17%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
2 |
8 |
4 |
Pleural thickening
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
1 |
2 |
Pleurisy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
1 |
2 |
Pneumonia aspiration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Pneumonitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Pneumothorax
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Productive cough
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
15 / 3581 (0.42%) |
14 / 3576 (0.39%) |
20 / 3581 (0.56%) |
occurrences all number
|
10 |
15 |
14 |
20 |
Pulmonary arterial hypertension
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
2 |
1 |
Pulmonary artery thrombosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Pulmonary calcification
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Pulmonary cavitation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Pulmonary congestion
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
5 / 3576 (0.14%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
2 |
5 |
5 |
Pulmonary embolism
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Pulmonary fibrosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
4 |
2 |
Pulmonary granuloma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Pulmonary hypertension
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
9 / 3581 (0.25%) |
5 / 3576 (0.14%) |
18 / 3581 (0.50%) |
occurrences all number
|
3 |
9 |
5 |
18 |
Pulmonary infarction
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Pulmonary mass
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
1 |
5 |
4 |
Pulmonary oedema
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Pulmonary pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Rales
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
4 |
3 |
Reflux laryngitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Respiratory acidosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Respiratory disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Respiratory distress
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Respiratory failure
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
3 |
2 |
Rhinalgia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Rhinitis allergic
|
|
|
|
|
subjects affected / exposed
|
26 / 3576 (0.73%) |
23 / 3581 (0.64%) |
39 / 3576 (1.09%) |
32 / 3581 (0.89%) |
occurrences all number
|
26 |
24 |
39 |
34 |
Rhinorrhoea
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
9 / 3581 (0.25%) |
14 / 3576 (0.39%) |
15 / 3581 (0.42%) |
occurrences all number
|
7 |
9 |
15 |
15 |
Sinus congestion
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
4 |
1 |
Sinus disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
2 |
Sinus polyp
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Sleep apnoea syndrome
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
7 / 3581 (0.20%) |
occurrences all number
|
2 |
2 |
4 |
7 |
Sneezing
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Sputum discoloured
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Sputum retention
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Throat irritation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
5 / 3581 (0.14%) |
occurrences all number
|
1 |
2 |
1 |
5 |
Throat tightness
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Tonsillar hypertrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Tonsillar inflammation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Tonsillolith
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Upper respiratory tract congestion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Upper respiratory tract inflammation
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
6 / 3576 (0.17%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
2 |
7 |
4 |
Upper-airway cough syndrome
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
0 |
3 |
1 |
Vasomotor rhinitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Vocal cord disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Vocal cord thickening
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Wheezing
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
2 |
1 |
3 |
Psychiatric disorders
|
|
|
|
|
Abnormal behaviour
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
2 |
2 |
2 |
Abnormal dreams
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Acute stress disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Adjustment disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
2 |
3 |
2 |
Adjustment disorder with depressed mood
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
occurrences all number
|
4 |
3 |
4 |
3 |
Affective disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
2 |
1 |
Agitation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Alcohol abuse
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Alcoholic hangover
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Anxiety
|
|
|
|
|
subjects affected / exposed
|
27 / 3576 (0.76%) |
25 / 3581 (0.70%) |
37 / 3576 (1.03%) |
42 / 3581 (1.17%) |
occurrences all number
|
29 |
25 |
39 |
42 |
Anxiety disorder
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
2 / 3581 (0.06%) |
16 / 3576 (0.45%) |
6 / 3581 (0.17%) |
occurrences all number
|
8 |
2 |
17 |
6 |
Anxiety disorder due to a general medical condition
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Bipolar II disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Bipolar disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Bruxism
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Bulimia nervosa
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Cardiovascular somatic symptom disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Confusional state
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
3 |
3 |
Conversion disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Delirium
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
0 |
5 |
3 |
Depressed mood
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
5 / 3581 (0.14%) |
12 / 3576 (0.34%) |
7 / 3581 (0.20%) |
occurrences all number
|
6 |
5 |
12 |
7 |
Depression
|
|
|
|
|
subjects affected / exposed
|
42 / 3576 (1.17%) |
47 / 3581 (1.31%) |
93 / 3576 (2.60%) |
78 / 3581 (2.18%) |
occurrences all number
|
43 |
47 |
100 |
81 |
Depressive symptom
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Disorientation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Emotional disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Encopresis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Feelings of worthlessness
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
3 |
0 |
Grief reaction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hallucination
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Hallucination, auditory
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Head banging
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Illusion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Initial insomnia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Insomnia
|
|
|
|
|
subjects affected / exposed
|
68 / 3576 (1.90%) |
72 / 3581 (2.01%) |
101 / 3576 (2.82%) |
105 / 3581 (2.93%) |
occurrences all number
|
70 |
75 |
110 |
112 |
Irritability
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Listless
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Major depression
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
occurrences all number
|
3 |
0 |
4 |
0 |
Mental disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Mental fatigue
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Middle insomnia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Mood altered
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
0 |
2 |
1 |
Mood disorder due to a general medical condition
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Nervousness
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Neurosis
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
2 |
4 |
2 |
Nicotine dependence
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Panic attack
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
0 |
3 |
3 |
Panic disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Persistent depressive disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Personality change due to a general medical condition
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Post-traumatic stress disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Psychotic disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Psychotic disorder due to a general medical condition
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Restlessness
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
2 |
3 |
2 |
Schizophreniform disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Sleep disorder
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
7 / 3581 (0.20%) |
9 / 3576 (0.25%) |
9 / 3581 (0.25%) |
occurrences all number
|
7 |
7 |
9 |
10 |
Somatic symptom disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Stress
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
9 / 3576 (0.25%) |
5 / 3581 (0.14%) |
occurrences all number
|
6 |
3 |
9 |
5 |
Tic
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Withdrawal syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Product issues
|
|
|
|
|
Device breakage
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
5 / 3581 (0.14%) |
5 / 3576 (0.14%) |
6 / 3581 (0.17%) |
occurrences all number
|
6 |
5 |
6 |
6 |
Device dislocation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Device extrusion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Device failure
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
6 / 3581 (0.17%) |
3 / 3576 (0.08%) |
7 / 3581 (0.20%) |
occurrences all number
|
3 |
7 |
3 |
10 |
Device loosening
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Device malfunction
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Hepatobiliary disorders
|
|
|
|
|
Alcoholic liver disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Bile duct obstruction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Bile duct stone
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
2 |
2 |
3 |
Biliary colic
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
0 |
5 |
1 |
Biliary cyst
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Biliary dilatation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
2 |
2 |
Biliary tract disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Cholangitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
1 |
0 |
3 |
Cholecystitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
0 |
1 |
2 |
Cholecystitis chronic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Cholelithiasis
|
|
|
|
|
subjects affected / exposed
|
22 / 3576 (0.62%) |
20 / 3581 (0.56%) |
44 / 3576 (1.23%) |
37 / 3581 (1.03%) |
occurrences all number
|
22 |
20 |
45 |
37 |
Drug-induced liver injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Fatty liver alcoholic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Gallbladder cholesterolosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Gallbladder polyp
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
6 |
2 |
Hepatic calcification
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hepatic cirrhosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Hepatic cyst
|
|
|
|
|
subjects affected / exposed
|
18 / 3576 (0.50%) |
6 / 3581 (0.17%) |
28 / 3576 (0.78%) |
10 / 3581 (0.28%) |
occurrences all number
|
18 |
6 |
29 |
10 |
Hepatic failure
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hepatic function abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Hepatic lesion
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hepatic steatosis
|
|
|
|
|
subjects affected / exposed
|
21 / 3576 (0.59%) |
18 / 3581 (0.50%) |
35 / 3576 (0.98%) |
35 / 3581 (0.98%) |
occurrences all number
|
25 |
18 |
39 |
35 |
Hepatitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hepatobiliary disease
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Hepatomegaly
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Hydrocholecystis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hyperbilirubinaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Hypertransaminasaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Jaundice
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
2 |
2 |
Liver disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
4 |
3 |
Pneumobilia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Portal hypertension
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Investigations
|
|
|
|
|
Abdominal bruit
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Alanine aminotransferase increased
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
4 / 3581 (0.11%) |
16 / 3576 (0.45%) |
8 / 3581 (0.22%) |
occurrences all number
|
7 |
4 |
16 |
8 |
Amylase increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Antinuclear antibody increased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Aortic bruit
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Arterial bruit
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Arteriogram coronary abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Aspartate aminotransferase increased
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
3 / 3581 (0.08%) |
16 / 3576 (0.45%) |
7 / 3581 (0.20%) |
occurrences all number
|
9 |
3 |
17 |
7 |
Aspiration bronchial
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Bacterial test
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Beta 2 microglobulin increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Blood albumin decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Blood alkaline phosphatase increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
1 |
4 |
Blood bicarbonate decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Blood bilirubin increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Blood calcium increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Blood chloride decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Blood cholesterol increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
5 / 3581 (0.14%) |
occurrences all number
|
0 |
2 |
1 |
5 |
Blood creatine phosphokinase increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Blood creatinine increased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Blood folate decreased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Blood glucose abnormal
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
3 |
1 |
4 |
Blood glucose increased
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
6 / 3576 (0.17%) |
5 / 3581 (0.14%) |
occurrences all number
|
4 |
0 |
6 |
6 |
Blood immunoglobulin G increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Blood iron decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Blood iron increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Blood parathyroid hormone increased
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Blood potassium decreased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
2 |
2 |
Blood potassium increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Blood pressure decreased
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
3 |
0 |
3 |
0 |
Blood pressure increased
|
|
|
|
|
subjects affected / exposed
|
21 / 3576 (0.59%) |
13 / 3581 (0.36%) |
39 / 3576 (1.09%) |
25 / 3581 (0.70%) |
occurrences all number
|
21 |
13 |
42 |
25 |
Blood pressure systolic increased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Blood sodium decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Blood thyroid stimulating hormone increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Blood urea increased
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
1 |
5 |
1 |
Blood uric acid increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
1 |
2 |
Body height abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Body height decreased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
2 / 3576 (0.06%) |
9 / 3581 (0.25%) |
occurrences all number
|
1 |
4 |
2 |
9 |
Body mass index increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Body temperature increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
3 |
0 |
3 |
Bone density decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Brain scan abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Breath sounds abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
C-reactive protein increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Cardiac murmur
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
2 / 3581 (0.06%) |
16 / 3576 (0.45%) |
12 / 3581 (0.34%) |
occurrences all number
|
9 |
2 |
16 |
12 |
Carotid bruit
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Carotid pulse abnormal
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Carotid pulse increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Chest X-ray abnormal
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
8 / 3576 (0.22%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
1 |
9 |
5 |
Coagulation time prolonged
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Computerised tomogram head abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Creatinine renal clearance decreased
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
3 |
1 |
Creatinine renal clearance increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Ejection fraction decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Electrocardiogram Q wave abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Electrocardiogram ST segment elevation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Electrocardiogram T wave abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Electrocardiogram abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Electrocardiogram repolarisation abnormality
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Eosinophil count increased
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Faecal calprotectin increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Fibrin D dimer increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
3 |
Gamma-glutamyltransferase increased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Glomerular filtration rate abnormal
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Glomerular filtration rate decreased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Glycosylated haemoglobin increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Grip strength decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Haemoglobin decreased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
4 |
1 |
Heart rate increased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Heart rate irregular
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
1 |
2 |
3 |
Helicobacter test positive
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
3 |
0 |
Hepatic enzyme abnormal
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hepatic enzyme increased
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
occurrences all number
|
5 |
1 |
5 |
2 |
Hepatitis A antibody positive
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hepatitis B surface antigen positive
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hepatitis C virus test positive
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Hepatobiliary scan abnormal
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Human epidermal growth factor receptor decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Intraocular pressure increased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
1 |
2 |
Liver function test abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
2 |
2 |
Liver function test increased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Low density lipoprotein increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Lymphocyte count decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Lymphocyte morphology abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Mammogram abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Monocyte count increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Neutrophil count decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Neutrophil count increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Occult blood
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
1 |
2 |
Occult blood positive
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
2 |
1 |
4 |
Pancreatic enzymes increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Platelet count decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Platelet count increased
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
2 |
3 |
Protein total increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Pulmonary arterial pressure increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Red blood cell sedimentation rate increased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Reticulocyte count decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Rheumatoid factor positive
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Thyroid function test abnormal
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Transaminases increased
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
10 / 3576 (0.28%) |
5 / 3581 (0.14%) |
occurrences all number
|
4 |
2 |
11 |
5 |
Tuberculin test positive
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Ultrasound liver abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Urinary system X-ray
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Urine output decreased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Valsalva maneuver
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Vitamin B12 increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Weight decreased
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
23 / 3581 (0.64%) |
45 / 3576 (1.26%) |
54 / 3581 (1.51%) |
occurrences all number
|
12 |
24 |
46 |
57 |
Weight increased
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
7 / 3581 (0.20%) |
15 / 3576 (0.42%) |
11 / 3581 (0.31%) |
occurrences all number
|
11 |
7 |
15 |
11 |
White blood cell count decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
3 |
White blood cell count increased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
X-ray abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Injury, poisoning and procedural complications
|
|
|
|
|
Abdominal injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Accident at work
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Accidental exposure to product
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Anaemia postoperative
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
4 / 3576 (0.11%) |
6 / 3581 (0.17%) |
occurrences all number
|
2 |
3 |
4 |
6 |
Animal bite
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
4 / 3581 (0.11%) |
18 / 3576 (0.50%) |
7 / 3581 (0.20%) |
occurrences all number
|
11 |
4 |
20 |
7 |
Animal scratch
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Arthropod bite
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
18 / 3581 (0.50%) |
17 / 3576 (0.48%) |
28 / 3581 (0.78%) |
occurrences all number
|
14 |
19 |
19 |
30 |
Arthropod sting
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
9 / 3581 (0.25%) |
occurrences all number
|
0 |
2 |
1 |
11 |
Back injury
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
7 / 3576 (0.20%) |
2 / 3581 (0.06%) |
occurrences all number
|
4 |
1 |
7 |
2 |
Bladder injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Bone contusion
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
3 |
1 |
Bone fissure
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Brain contusion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Breast injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Burns first degree
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
2 |
3 |
Burns second degree
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
4 |
3 |
Buttock injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Cartilage injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Cataract operation complication
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
3 |
Chemical burn of skin
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Chest crushing
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Chest injury
|
|
|
|
|
subjects affected / exposed
|
15 / 3576 (0.42%) |
5 / 3581 (0.14%) |
29 / 3576 (0.81%) |
11 / 3581 (0.31%) |
occurrences all number
|
16 |
5 |
30 |
11 |
Clavicle fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
occurrences all number
|
1 |
2 |
3 |
5 |
Concussion
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Conjunctival laceration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Contusion
|
|
|
|
|
subjects affected / exposed
|
122 / 3576 (3.41%) |
102 / 3581 (2.85%) |
204 / 3576 (5.70%) |
179 / 3581 (5.00%) |
occurrences all number
|
151 |
119 |
270 |
212 |
Corneal abrasion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Craniocerebral injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
3 |
4 |
4 |
Crushing injury of trunk
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Deafness traumatic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Epicondylitis
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
9 / 3581 (0.25%) |
17 / 3576 (0.48%) |
12 / 3581 (0.34%) |
occurrences all number
|
10 |
9 |
17 |
13 |
Eschar
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Excoriation
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
7 / 3576 (0.20%) |
11 / 3581 (0.31%) |
occurrences all number
|
2 |
5 |
9 |
11 |
Exposure to communicable disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
3 |
Eye burns
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Eye contusion
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
8 / 3576 (0.22%) |
4 / 3581 (0.11%) |
occurrences all number
|
5 |
2 |
8 |
5 |
Eye injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
2 |
2 |
Eye operation complication
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Eyelid injury
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Face injury
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
5 / 3581 (0.14%) |
13 / 3576 (0.36%) |
9 / 3581 (0.25%) |
occurrences all number
|
10 |
6 |
14 |
10 |
Facial bones fracture
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
0 |
4 |
2 |
Fall
|
|
|
|
|
subjects affected / exposed
|
319 / 3576 (8.92%) |
255 / 3581 (7.12%) |
539 / 3576 (15.07%) |
484 / 3581 (13.52%) |
occurrences all number
|
378 |
321 |
801 |
676 |
Femoral neck fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Femur fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Fibula fracture
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
4 / 3581 (0.11%) |
12 / 3576 (0.34%) |
10 / 3581 (0.28%) |
occurrences all number
|
6 |
4 |
13 |
10 |
Foot fracture
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
11 / 3581 (0.31%) |
28 / 3576 (0.78%) |
22 / 3581 (0.61%) |
occurrences all number
|
13 |
11 |
28 |
23 |
Foreign body
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
3 |
2 |
Foreign body in eye
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Fractured ischium
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Gastrointestinal injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Gingival injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Glaucoma traumatic
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Graft complication
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hand fracture
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
4 / 3581 (0.11%) |
25 / 3576 (0.70%) |
9 / 3581 (0.25%) |
occurrences all number
|
14 |
4 |
27 |
9 |
Head injury
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
13 / 3581 (0.36%) |
24 / 3576 (0.67%) |
22 / 3581 (0.61%) |
occurrences all number
|
14 |
13 |
24 |
24 |
Heat exhaustion
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Heat illness
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
3 |
Humerus fracture
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
9 / 3576 (0.25%) |
9 / 3581 (0.25%) |
occurrences all number
|
2 |
5 |
9 |
9 |
Hypobarism
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Iliotibial band syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Incision site pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Incisional hernia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Injury
|
|
|
|
|
subjects affected / exposed
|
18 / 3576 (0.50%) |
14 / 3581 (0.39%) |
22 / 3576 (0.62%) |
22 / 3581 (0.61%) |
occurrences all number
|
18 |
15 |
23 |
23 |
Injury corneal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Joint dislocation
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
5 / 3581 (0.14%) |
12 / 3576 (0.34%) |
13 / 3581 (0.36%) |
occurrences all number
|
9 |
8 |
13 |
18 |
Joint injury
|
|
|
|
|
subjects affected / exposed
|
60 / 3576 (1.68%) |
44 / 3581 (1.23%) |
98 / 3576 (2.74%) |
75 / 3581 (2.09%) |
occurrences all number
|
67 |
47 |
115 |
87 |
Laceration
|
|
|
|
|
subjects affected / exposed
|
17 / 3576 (0.48%) |
11 / 3581 (0.31%) |
32 / 3576 (0.89%) |
28 / 3581 (0.78%) |
occurrences all number
|
17 |
11 |
33 |
32 |
Ligament injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Ligament rupture
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
3 |
0 |
Ligament sprain
|
|
|
|
|
subjects affected / exposed
|
38 / 3576 (1.06%) |
30 / 3581 (0.84%) |
60 / 3576 (1.68%) |
55 / 3581 (1.54%) |
occurrences all number
|
42 |
33 |
72 |
59 |
Limb injury
|
|
|
|
|
subjects affected / exposed
|
54 / 3576 (1.51%) |
65 / 3581 (1.82%) |
97 / 3576 (2.71%) |
106 / 3581 (2.96%) |
occurrences all number
|
59 |
71 |
104 |
121 |
Lip injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
2 |
2 |
3 |
Lumbar vertebral fracture
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
1 |
2 |
3 |
Mallet finger
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Meniscus injury
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
12 / 3576 (0.34%) |
6 / 3581 (0.17%) |
occurrences all number
|
8 |
1 |
15 |
6 |
Mouth injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Multiple injuries
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
3 |
1 |
Muscle injury
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
6 / 3581 (0.17%) |
occurrences all number
|
2 |
1 |
3 |
6 |
Muscle rupture
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
2 |
1 |
Muscle strain
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
12 / 3581 (0.34%) |
23 / 3576 (0.64%) |
17 / 3581 (0.47%) |
occurrences all number
|
13 |
12 |
24 |
18 |
Musculoskeletal injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Nail injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
4 |
0 |
4 |
Nasal injury
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
occurrences all number
|
5 |
3 |
6 |
3 |
Neck injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Nerve injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Overdose
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
3 |
1 |
4 |
Patella fracture
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
1 |
4 |
2 |
Perineal injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Periorbital haematoma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
0 |
3 |
3 |
Periorbital haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Perirenal haematoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Peroneal nerve injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Post procedural complication
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Post procedural contusion
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
3 |
1 |
Post procedural fistula
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Post procedural haematoma
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
1 |
3 |
1 |
Post procedural haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
2 |
2 |
Post procedural hypothyroidism
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Post procedural inflammation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Post procedural swelling
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
3 |
1 |
Post-traumatic neck syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Post-traumatic pain
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
9 / 3581 (0.25%) |
17 / 3576 (0.48%) |
10 / 3581 (0.28%) |
occurrences all number
|
14 |
10 |
18 |
11 |
Postoperative hernia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Postoperative ileus
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Postoperative wound complication
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Postpericardiotomy syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Procedural complication
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Procedural dizziness
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Procedural haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Procedural headache
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Procedural pain
|
|
|
|
|
subjects affected / exposed
|
27 / 3576 (0.76%) |
22 / 3581 (0.61%) |
40 / 3576 (1.12%) |
34 / 3581 (0.95%) |
occurrences all number
|
27 |
23 |
43 |
36 |
Procedural pneumothorax
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Pubis fracture
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
occurrences all number
|
4 |
0 |
4 |
0 |
Pulmonary contusion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Radiation associated pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Radiation proctitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Radiation skin injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Radius fracture
|
|
|
|
|
subjects affected / exposed
|
25 / 3576 (0.70%) |
22 / 3581 (0.61%) |
52 / 3576 (1.45%) |
52 / 3581 (1.45%) |
occurrences all number
|
25 |
22 |
53 |
53 |
Rib fracture
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
3 / 3581 (0.08%) |
21 / 3576 (0.59%) |
6 / 3581 (0.17%) |
occurrences all number
|
12 |
3 |
22 |
6 |
Road traffic accident
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
12 / 3581 (0.34%) |
14 / 3576 (0.39%) |
16 / 3581 (0.45%) |
occurrences all number
|
10 |
13 |
14 |
17 |
Scar
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Scratch
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
occurrences all number
|
5 |
1 |
5 |
1 |
Seroma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Skeletal injury
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
0 |
3 |
1 |
Skin abrasion
|
|
|
|
|
subjects affected / exposed
|
15 / 3576 (0.42%) |
11 / 3581 (0.31%) |
23 / 3576 (0.64%) |
23 / 3581 (0.64%) |
occurrences all number
|
16 |
11 |
26 |
26 |
Skin injury
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
4 |
2 |
4 |
2 |
Skin wound
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
3 |
2 |
Skull fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Soft tissue injury
|
|
|
|
|
subjects affected / exposed
|
37 / 3576 (1.03%) |
28 / 3581 (0.78%) |
47 / 3576 (1.31%) |
32 / 3581 (0.89%) |
occurrences all number
|
39 |
35 |
53 |
40 |
Spinal column injury
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
2 |
5 |
5 |
Spinal compression fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
1 |
2 |
Spinal fracture
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
4 |
2 |
Splinter
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Stab wound
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Sternal fracture
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Sternal injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Subarachnoid haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Subcutaneous haematoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Subdural haematoma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Sunburn
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
3 |
0 |
Suture related complication
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Synovial rupture
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Tendon injury
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
0 |
3 |
1 |
Tendon rupture
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
4 / 3576 (0.11%) |
7 / 3581 (0.20%) |
occurrences all number
|
4 |
4 |
7 |
7 |
Thermal burn
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
9 / 3581 (0.25%) |
23 / 3576 (0.64%) |
14 / 3581 (0.39%) |
occurrences all number
|
11 |
9 |
24 |
14 |
Thoracic vertebral fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
1 |
2 |
Tibia fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
3 |
1 |
Tongue injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Tooth fracture
|
|
|
|
|
subjects affected / exposed
|
28 / 3576 (0.78%) |
31 / 3581 (0.87%) |
54 / 3576 (1.51%) |
61 / 3581 (1.70%) |
occurrences all number
|
29 |
34 |
62 |
71 |
Tooth injury
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
6 / 3576 (0.17%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
1 |
6 |
5 |
Toxicity to various agents
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Traumatic haematoma
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
occurrences all number
|
5 |
3 |
5 |
3 |
Traumatic haemorrhage
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
5 |
0 |
Traumatic lung injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Traumatic ulcer
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Ulna fracture
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
5 / 3581 (0.14%) |
20 / 3576 (0.56%) |
15 / 3581 (0.42%) |
occurrences all number
|
8 |
5 |
21 |
16 |
Ulnar nerve injury
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Vaccination complication
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Vascular injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Wound
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
20 / 3581 (0.56%) |
30 / 3576 (0.84%) |
35 / 3581 (0.98%) |
occurrences all number
|
10 |
21 |
30 |
38 |
Wound secretion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Wrist fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Congenital, familial and genetic disorders
|
|
|
|
|
Adenomatous polyposis coli
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Arteriovenous malformation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Bartter's syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Birth mark
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Congenital cystic kidney disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Cortical dysplasia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Dermoid cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Dolichocolon
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Epidermolysis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Extrarenal pelvis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Fibrous dysplasia of bone
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Gastrointestinal disorder congenital
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Hypertrophic cardiomyopathy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Intracranial lipoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Polycystic liver disease
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Porokeratosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Protein C deficiency
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Renal hypoplasia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Sacralisation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Spina bifida
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Spine malformation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Syringomyelia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Type IIa hyperlipidaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Vertebral artery hypoplasia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Cardiac disorders
|
|
|
|
|
Acute myocardial infarction
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Angina pectoris
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
7 / 3581 (0.20%) |
23 / 3576 (0.64%) |
17 / 3581 (0.47%) |
occurrences all number
|
14 |
10 |
24 |
20 |
Angina unstable
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Aortic valve calcification
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Aortic valve disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Aortic valve incompetence
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
7 / 3581 (0.20%) |
17 / 3576 (0.48%) |
15 / 3581 (0.42%) |
occurrences all number
|
7 |
7 |
17 |
15 |
Aortic valve sclerosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
1 |
3 |
Aortic valve stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
4 |
1 |
Arrhythmia
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
8 / 3581 (0.22%) |
18 / 3576 (0.50%) |
17 / 3581 (0.47%) |
occurrences all number
|
10 |
8 |
18 |
17 |
Arrhythmia supraventricular
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
0 |
3 |
2 |
Arteriosclerosis coronary artery
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
4 |
1 |
Atrial fibrillation
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
13 / 3581 (0.36%) |
34 / 3576 (0.95%) |
26 / 3581 (0.73%) |
occurrences all number
|
15 |
18 |
38 |
34 |
Atrial flutter
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
2 |
2 |
Atrial tachycardia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Atrioventricular block first degree
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
1 |
6 |
2 |
Atrioventricular block second degree
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Bradycardia
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
7 / 3581 (0.20%) |
9 / 3576 (0.25%) |
20 / 3581 (0.56%) |
occurrences all number
|
5 |
7 |
9 |
21 |
Bundle branch block left
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
6 / 3581 (0.17%) |
5 / 3576 (0.14%) |
12 / 3581 (0.34%) |
occurrences all number
|
0 |
7 |
5 |
13 |
Bundle branch block right
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
10 / 3576 (0.28%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
2 |
10 |
4 |
Cardiac aneurysm
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Cardiac disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
2 |
0 |
3 |
Cardiac failure
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
7 / 3581 (0.20%) |
11 / 3576 (0.31%) |
16 / 3581 (0.45%) |
occurrences all number
|
7 |
7 |
12 |
16 |
Cardiac failure acute
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Cardiac failure chronic
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
9 / 3581 (0.25%) |
occurrences all number
|
3 |
4 |
9 |
9 |
Cardiac failure congestive
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
5 / 3581 (0.14%) |
occurrences all number
|
5 |
1 |
6 |
5 |
Cardiac hypertrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Cardiac septal hypertrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
2 |
1 |
3 |
Cardiac valve disease
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
4 |
2 |
5 |
Cardiac valve sclerosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Cardiac ventricular disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Cardiomegaly
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
6 / 3581 (0.17%) |
7 / 3576 (0.20%) |
11 / 3581 (0.31%) |
occurrences all number
|
5 |
6 |
7 |
11 |
Cardiomyopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Cardiovascular disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Cardiovascular insufficiency
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Conduction disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Congestive cardiomyopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Coronary artery disease
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
7 / 3581 (0.20%) |
14 / 3576 (0.39%) |
11 / 3581 (0.31%) |
occurrences all number
|
7 |
7 |
15 |
11 |
Coronary artery insufficiency
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
2 |
3 |
Coronary artery occlusion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Cyanosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Degenerative aortic valve disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Degenerative mitral valve disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Diastolic dysfunction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
3 |
2 |
4 |
Dilatation atrial
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
5 / 3581 (0.14%) |
occurrences all number
|
1 |
3 |
1 |
5 |
Extrasystoles
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
7 / 3576 (0.20%) |
3 / 3581 (0.08%) |
occurrences all number
|
4 |
2 |
7 |
3 |
Heart valve calcification
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Heart valve incompetence
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
7 / 3576 (0.20%) |
9 / 3581 (0.25%) |
occurrences all number
|
3 |
3 |
7 |
10 |
Hypertensive cardiomegaly
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
2 |
3 |
2 |
Hypertensive cardiomyopathy
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
0 |
4 |
1 |
Hypertensive heart disease
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
4 / 3576 (0.11%) |
6 / 3581 (0.17%) |
occurrences all number
|
2 |
4 |
4 |
6 |
Intracardiac thrombus
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Ischaemic cardiomyopathy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
0 |
2 |
3 |
Left atrial dilatation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
3 |
1 |
Left atrial enlargement
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
2 |
1 |
Left atrial hypertrophy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Left ventricular dysfunction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
5 |
3 |
Left ventricular failure
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Left ventricular hypertrophy
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
4 |
4 |
5 |
Low cardiac output syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Mitral valve calcification
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Mitral valve disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Mitral valve incompetence
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
11 / 3581 (0.31%) |
27 / 3576 (0.76%) |
28 / 3581 (0.78%) |
occurrences all number
|
8 |
11 |
28 |
28 |
Mitral valve prolapse
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
2 |
3 |
Mitral valve sclerosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
2 |
0 |
3 |
Mitral valve stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Myocardial infarction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Myocardial ischaemia
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
12 / 3581 (0.34%) |
occurrences all number
|
2 |
4 |
9 |
12 |
Palpitations
|
|
|
|
|
subjects affected / exposed
|
27 / 3576 (0.76%) |
24 / 3581 (0.67%) |
35 / 3576 (0.98%) |
35 / 3581 (0.98%) |
occurrences all number
|
27 |
24 |
36 |
36 |
Pericardial effusion
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Pericarditis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Pulmonary valve incompetence
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Right atrial enlargement
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Right ventricular dysfunction
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Right ventricular enlargement
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Right ventricular hypertrophy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Sinus arrhythmia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Sinus bradycardia
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
5 / 3576 (0.14%) |
7 / 3581 (0.20%) |
occurrences all number
|
2 |
5 |
5 |
7 |
Sinus node dysfunction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Sinus tachycardia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
0 / 3576 (0.00%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
3 |
0 |
4 |
Supraventricular extrasystoles
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
7 / 3581 (0.20%) |
occurrences all number
|
4 |
4 |
9 |
7 |
Supraventricular tachycardia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
occurrences all number
|
1 |
2 |
2 |
5 |
Systolic dysfunction
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Tachyarrhythmia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Tachycardia
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
12 / 3581 (0.34%) |
16 / 3576 (0.45%) |
18 / 3581 (0.50%) |
occurrences all number
|
10 |
15 |
19 |
22 |
Tachycardia paroxysmal
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
2 |
3 |
2 |
Tricuspid valve incompetence
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
9 / 3581 (0.25%) |
20 / 3576 (0.56%) |
22 / 3581 (0.61%) |
occurrences all number
|
4 |
9 |
20 |
22 |
Tricuspid valve stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Ventricular arrhythmia
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
3 |
2 |
Ventricular extrasystoles
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
7 / 3581 (0.20%) |
9 / 3576 (0.25%) |
9 / 3581 (0.25%) |
occurrences all number
|
4 |
7 |
9 |
9 |
Ventricular hypertrophy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Ventricular hypokinesia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
2 |
2 |
Nervous system disorders
|
|
|
|
|
Acoustic neuritis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Akathisia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Altered state of consciousness
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Amnesia
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
10 / 3581 (0.28%) |
9 / 3576 (0.25%) |
15 / 3581 (0.42%) |
occurrences all number
|
7 |
10 |
10 |
15 |
Aphonia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Arachnoid cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Autonomic nervous system imbalance
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Balance disorder
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
10 / 3581 (0.28%) |
8 / 3576 (0.22%) |
13 / 3581 (0.36%) |
occurrences all number
|
7 |
11 |
9 |
14 |
Brain injury
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Burning feet syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Burning sensation
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
8 / 3581 (0.22%) |
9 / 3576 (0.25%) |
13 / 3581 (0.36%) |
occurrences all number
|
6 |
8 |
9 |
14 |
Carotid arteriosclerosis
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
12 / 3576 (0.34%) |
8 / 3581 (0.22%) |
occurrences all number
|
4 |
4 |
13 |
8 |
Carotid artery disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Carotid artery stenosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
6 / 3576 (0.17%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
7 |
0 |
Carpal tunnel syndrome
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
9 / 3581 (0.25%) |
27 / 3576 (0.76%) |
17 / 3581 (0.47%) |
occurrences all number
|
16 |
9 |
33 |
18 |
Central nervous system lesion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Cerebellar atrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Cerebellar syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Cerebral arteriosclerosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
occurrences all number
|
1 |
2 |
2 |
6 |
Cerebral artery stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Cerebral atrophy
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
6 / 3576 (0.17%) |
10 / 3581 (0.28%) |
occurrences all number
|
4 |
5 |
6 |
10 |
Cerebral calcification
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Cerebral disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Cerebral haematoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
2 |
2 |
Cerebral haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Cerebral infarction
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Cerebral ischaemia
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
8 / 3576 (0.22%) |
8 / 3581 (0.22%) |
occurrences all number
|
4 |
4 |
9 |
9 |
Cerebral microangiopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
1 |
0 |
4 |
Cerebrosclerosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Cerebrovascular accident
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
1 |
2 |
Cerebrovascular disorder
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
4 / 3581 (0.11%) |
11 / 3576 (0.31%) |
7 / 3581 (0.20%) |
occurrences all number
|
8 |
4 |
12 |
7 |
Cerebrovascular insufficiency
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Cervical myelopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Cervical radiculopathy
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
7 / 3576 (0.20%) |
7 / 3581 (0.20%) |
occurrences all number
|
3 |
2 |
7 |
7 |
Cervicobrachial syndrome
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
7 / 3576 (0.20%) |
5 / 3581 (0.14%) |
occurrences all number
|
4 |
2 |
7 |
5 |
Cognitive disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
6 / 3581 (0.17%) |
occurrences all number
|
1 |
0 |
4 |
6 |
Complex regional pain syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
1 |
2 |
Cranial nerve disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Dementia
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
1 |
6 |
5 |
Dementia Alzheimer's type
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
9 / 3576 (0.25%) |
5 / 3581 (0.14%) |
occurrences all number
|
4 |
3 |
9 |
5 |
Demyelination
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Diabetic neuropathy
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
7 / 3576 (0.20%) |
7 / 3581 (0.20%) |
occurrences all number
|
4 |
3 |
8 |
7 |
Dizziness
|
|
|
|
|
subjects affected / exposed
|
158 / 3576 (4.42%) |
154 / 3581 (4.30%) |
216 / 3576 (6.04%) |
228 / 3581 (6.37%) |
occurrences all number
|
181 |
174 |
259 |
264 |
Dizziness exertional
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
3 |
0 |
Dizziness postural
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
3 / 3576 (0.08%) |
7 / 3581 (0.20%) |
occurrences all number
|
4 |
3 |
4 |
7 |
Drooling
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Drug withdrawal headache
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Dysaesthesia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
4 |
2 |
5 |
Dysarthria
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Dysgeusia
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
5 / 3581 (0.14%) |
10 / 3576 (0.28%) |
7 / 3581 (0.20%) |
occurrences all number
|
8 |
6 |
11 |
8 |
Dyskinesia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Dysphonia psychogenic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Encephalopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Epilepsy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
4 |
1 |
Essential tremor
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
3 |
1 |
Extrapyramidal disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Facial neuralgia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Facial paralysis
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
14 / 3576 (0.39%) |
8 / 3581 (0.22%) |
occurrences all number
|
6 |
4 |
14 |
9 |
Generalised tonic-clonic seizure
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Haemorrhagic stroke
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Head discomfort
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
2 |
2 |
Headache
|
|
|
|
|
subjects affected / exposed
|
206 / 3576 (5.76%) |
235 / 3581 (6.56%) |
270 / 3576 (7.55%) |
293 / 3581 (8.18%) |
occurrences all number
|
240 |
270 |
327 |
352 |
Hemianopia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Hemianopia heteronymous
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hemiparesis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
3 |
2 |
Hydrocephalus
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Hyperaesthesia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hypersomnia
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
occurrences all number
|
4 |
0 |
4 |
0 |
Hypoaesthesia
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
36 / 3581 (1.01%) |
31 / 3576 (0.87%) |
48 / 3581 (1.34%) |
occurrences all number
|
22 |
43 |
34 |
57 |
Hyposmia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hypotonia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Intercostal neuralgia
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
4 / 3581 (0.11%) |
11 / 3576 (0.31%) |
6 / 3581 (0.17%) |
occurrences all number
|
11 |
4 |
13 |
6 |
Intracranial aneurysm
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
3 |
0 |
Ischaemic stroke
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
3 |
0 |
Lacunar infarction
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
0 |
2 |
2 |
Lethargy
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
0 |
4 |
2 |
Leukoencephalomyelitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Leukoencephalopathy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
1 |
4 |
3 |
Loss of consciousness
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
7 / 3576 (0.20%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
2 |
7 |
4 |
Lumbar radiculopathy
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
8 / 3576 (0.22%) |
10 / 3581 (0.28%) |
occurrences all number
|
3 |
5 |
9 |
14 |
Lumbosacral radiculopathy
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
3 |
0 |
Memory impairment
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
10 / 3581 (0.28%) |
27 / 3576 (0.76%) |
26 / 3581 (0.73%) |
occurrences all number
|
11 |
10 |
27 |
27 |
Migraine
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
12 / 3581 (0.34%) |
17 / 3576 (0.48%) |
16 / 3581 (0.45%) |
occurrences all number
|
16 |
13 |
24 |
17 |
Migraine with aura
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
2 |
2 |
Mononeuropathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Monoparesis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
1 |
3 |
Morton's neuralgia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Movement disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Multiple sclerosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Multiple sclerosis relapse
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Muscle contractions involuntary
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
3 |
2 |
Myasthenia gravis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Nerve compression
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
2 |
3 |
4 |
Nerve root compression
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
1 |
3 |
Nervous system disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Neuralgia
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
11 / 3581 (0.31%) |
10 / 3576 (0.28%) |
15 / 3581 (0.42%) |
occurrences all number
|
8 |
11 |
11 |
15 |
Neuritis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Neuropathy peripheral
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
6 / 3581 (0.17%) |
12 / 3576 (0.34%) |
13 / 3581 (0.36%) |
occurrences all number
|
9 |
6 |
13 |
13 |
Noninfective encephalitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Occipital neuralgia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Optic neuritis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Osmotic demyelination syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Paraesthesia
|
|
|
|
|
subjects affected / exposed
|
61 / 3576 (1.71%) |
72 / 3581 (2.01%) |
86 / 3576 (2.40%) |
87 / 3581 (2.43%) |
occurrences all number
|
65 |
83 |
96 |
101 |
Paraparesis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Parkinson's disease
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
10 / 3581 (0.28%) |
occurrences all number
|
4 |
4 |
9 |
10 |
Parkinsonism
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Parosmia
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
2 |
5 |
2 |
Peripheral motor neuropathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Peripheral nerve palsy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Peripheral nerve paresis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Peripheral sensorimotor neuropathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Peripheral sensory neuropathy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
2 |
1 |
Polyneuropathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
6 / 3581 (0.17%) |
occurrences all number
|
0 |
2 |
1 |
6 |
Poor quality sleep
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Post herpetic neuralgia
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
10 / 3576 (0.28%) |
10 / 3581 (0.28%) |
occurrences all number
|
4 |
4 |
10 |
10 |
Post polio syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Post-traumatic epilepsy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Post-traumatic headache
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Precerebral arteriosclerosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Presyncope
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
2 |
3 |
Pseudoradicular syndrome
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Psychomotor hyperactivity
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Radicular pain
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
6 / 3581 (0.17%) |
occurrences all number
|
1 |
3 |
2 |
6 |
Radicular syndrome
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
1 |
2 |
4 |
Radiculopathy
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
8 / 3581 (0.22%) |
7 / 3576 (0.20%) |
8 / 3581 (0.22%) |
occurrences all number
|
5 |
9 |
9 |
11 |
Restless legs syndrome
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
5 / 3576 (0.14%) |
6 / 3581 (0.17%) |
occurrences all number
|
3 |
4 |
5 |
7 |
Sciatic nerve neuropathy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Sciatica
|
|
|
|
|
subjects affected / exposed
|
42 / 3576 (1.17%) |
44 / 3581 (1.23%) |
87 / 3576 (2.43%) |
94 / 3581 (2.62%) |
occurrences all number
|
43 |
50 |
100 |
110 |
Sedation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Seizure
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
1 |
2 |
Senile dementia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Sinus headache
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Somnolence
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
11 / 3581 (0.31%) |
16 / 3576 (0.45%) |
13 / 3581 (0.36%) |
occurrences all number
|
13 |
11 |
19 |
13 |
Speech disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
2 |
2 |
Spinal cord disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Spinal meningeal cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Syncope
|
|
|
|
|
subjects affected / exposed
|
30 / 3576 (0.84%) |
20 / 3581 (0.56%) |
43 / 3576 (1.20%) |
41 / 3581 (1.14%) |
occurrences all number
|
31 |
21 |
49 |
44 |
Tarsal tunnel syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Tension headache
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
14 / 3581 (0.39%) |
16 / 3576 (0.45%) |
16 / 3581 (0.45%) |
occurrences all number
|
12 |
14 |
16 |
18 |
Tongue biting
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Transient ischaemic attack
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
3 |
5 |
4 |
Tremor
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
12 / 3581 (0.34%) |
14 / 3576 (0.39%) |
17 / 3581 (0.47%) |
occurrences all number
|
10 |
13 |
15 |
20 |
Trigeminal nerve paresis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Trigeminal neuralgia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
2 |
2 |
Trigeminal neuritis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
1 |
2 |
Unresponsive to stimuli
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
VIth nerve paralysis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Vascular dementia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Vascular encephalopathy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Vertebrobasilar insufficiency
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
1 |
2 |
3 |
Vertigo CNS origin
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Visual field defect
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
1 |
2 |
Vocal cord paralysis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
White matter lesion
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
0 |
2 |
2 |
Blood and lymphatic system disorders
|
|
|
|
|
Anaemia
|
|
|
|
|
subjects affected / exposed
|
57 / 3576 (1.59%) |
36 / 3581 (1.01%) |
124 / 3576 (3.47%) |
99 / 3581 (2.76%) |
occurrences all number
|
58 |
39 |
135 |
111 |
Anaemia folate deficiency
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Anaemia macrocytic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Anaemia megaloblastic
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Anaemia vitamin B12 deficiency
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Bandaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Basophilia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Blood disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Bone marrow failure
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Coagulopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Disseminated intravascular coagulation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Eosinophilia
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
6 / 3576 (0.17%) |
5 / 3581 (0.14%) |
occurrences all number
|
5 |
3 |
6 |
6 |
Febrile neutropenia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
0 |
5 |
Granulocytosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Haemorrhagic anaemia
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
3 |
1 |
Hypergammaglobulinaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Hyperglobulinaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hypochromic anaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Immune thrombocytopenic purpura
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Increased tendency to bruise
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
3 |
2 |
Iron deficiency anaemia
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
12 / 3581 (0.34%) |
16 / 3576 (0.45%) |
24 / 3581 (0.67%) |
occurrences all number
|
14 |
12 |
16 |
26 |
Leukocytosis
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
10 / 3576 (0.28%) |
9 / 3581 (0.25%) |
occurrences all number
|
3 |
3 |
10 |
9 |
Leukopenia
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
14 / 3581 (0.39%) |
21 / 3576 (0.59%) |
24 / 3581 (0.67%) |
occurrences all number
|
13 |
16 |
22 |
27 |
Lymph node calcification
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Lymph node pain
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Lymphadenitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
2 |
1 |
4 |
Lymphadenopathy
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
3 / 3581 (0.08%) |
8 / 3576 (0.22%) |
7 / 3581 (0.20%) |
occurrences all number
|
8 |
3 |
9 |
9 |
Lymphocytosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
3 |
1 |
5 |
Lymphopenia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Microcytic anaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
2 |
1 |
2 |
Nephrogenic anaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Neutropenia
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
8 / 3581 (0.22%) |
16 / 3576 (0.45%) |
17 / 3581 (0.47%) |
occurrences all number
|
12 |
9 |
16 |
22 |
Neutrophilia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
2 |
3 |
Normochromic normocytic anaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
5 / 3581 (0.14%) |
occurrences all number
|
0 |
0 |
1 |
5 |
Pancytopenia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
2 |
1 |
Polycythaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Sideroblastic anaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Splenomegaly
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Thrombocytopenia
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
4 / 3581 (0.11%) |
15 / 3576 (0.42%) |
11 / 3581 (0.31%) |
occurrences all number
|
6 |
4 |
17 |
11 |
Thrombocytosis
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
9 / 3581 (0.25%) |
occurrences all number
|
4 |
4 |
9 |
9 |
Ear and labyrinth disorders
|
|
|
|
|
Acute vestibular syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
3 |
Auditory disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Cerumen impaction
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
10 / 3581 (0.28%) |
17 / 3576 (0.48%) |
20 / 3581 (0.56%) |
occurrences all number
|
10 |
10 |
17 |
20 |
Conductive deafness
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
2 |
3 |
Deafness
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
1 |
4 |
1 |
Deafness bilateral
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
7 / 3576 (0.20%) |
6 / 3581 (0.17%) |
occurrences all number
|
4 |
4 |
7 |
6 |
Deafness neurosensory
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
occurrences all number
|
3 |
3 |
4 |
3 |
Deafness unilateral
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
3 |
3 |
5 |
Dysacusis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Ear congestion
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
3 |
2 |
3 |
3 |
Ear discomfort
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
3 |
1 |
Ear disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Ear pain
|
|
|
|
|
subjects affected / exposed
|
15 / 3576 (0.42%) |
14 / 3581 (0.39%) |
24 / 3576 (0.67%) |
22 / 3581 (0.61%) |
occurrences all number
|
15 |
15 |
27 |
23 |
Ear pruritus
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
3 |
2 |
3 |
3 |
Excessive cerumen production
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
8 / 3581 (0.22%) |
6 / 3576 (0.17%) |
11 / 3581 (0.31%) |
occurrences all number
|
3 |
8 |
6 |
11 |
External ear disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
External ear inflammation
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
4 |
2 |
Hypoacusis
|
|
|
|
|
subjects affected / exposed
|
16 / 3576 (0.45%) |
12 / 3581 (0.34%) |
21 / 3576 (0.59%) |
21 / 3581 (0.59%) |
occurrences all number
|
16 |
12 |
21 |
21 |
Inner ear disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Meniere's disease
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
9 / 3576 (0.25%) |
4 / 3581 (0.11%) |
occurrences all number
|
6 |
2 |
9 |
6 |
Middle ear effusion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Middle ear inflammation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Mixed deafness
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
3 |
2 |
3 |
Motion sickness
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
4 |
1 |
4 |
Neurosensory hypoacusis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Otorrhoea
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Otosclerosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
3 |
0 |
Presbyacusis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Sudden hearing loss
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
2 |
2 |
Tinnitus
|
|
|
|
|
subjects affected / exposed
|
29 / 3576 (0.81%) |
28 / 3581 (0.78%) |
42 / 3576 (1.17%) |
38 / 3581 (1.06%) |
occurrences all number
|
30 |
28 |
43 |
39 |
Tympanic membrane disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Tympanic membrane perforation
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
6 / 3576 (0.17%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
4 |
6 |
4 |
Tympanosclerosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Vertigo
|
|
|
|
|
subjects affected / exposed
|
80 / 3576 (2.24%) |
62 / 3581 (1.73%) |
117 / 3576 (3.27%) |
113 / 3581 (3.16%) |
occurrences all number
|
92 |
69 |
140 |
133 |
Vertigo labyrinthine
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Vertigo positional
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
6 / 3581 (0.17%) |
15 / 3576 (0.42%) |
9 / 3581 (0.25%) |
occurrences all number
|
10 |
6 |
17 |
9 |
Vestibular ataxia
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
1 |
4 |
1 |
Vestibular disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Eye disorders
|
|
|
|
|
Age-related macular degeneration
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
3 |
2 |
Amaurosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Amblyopia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Angle closure glaucoma
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
0 |
5 |
1 |
Arteriosclerotic retinopathy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Asthenopia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
1 |
1 |
4 |
Astigmatism
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Blepharitis
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
6 / 3581 (0.17%) |
10 / 3576 (0.28%) |
12 / 3581 (0.34%) |
occurrences all number
|
7 |
6 |
11 |
12 |
Blepharitis allergic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Blepharochalasis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Blindness transient
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Blindness unilateral
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Cataract
|
|
|
|
|
subjects affected / exposed
|
49 / 3576 (1.37%) |
66 / 3581 (1.84%) |
127 / 3576 (3.55%) |
152 / 3581 (4.24%) |
occurrences all number
|
60 |
84 |
151 |
191 |
Cataract diabetic
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Cataract nuclear
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Chalazion
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
occurrences all number
|
3 |
1 |
5 |
3 |
Chorioretinopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
5 |
Conjunctival haemorrhage
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
10 / 3581 (0.28%) |
9 / 3576 (0.25%) |
18 / 3581 (0.50%) |
occurrences all number
|
4 |
10 |
9 |
20 |
Conjunctival hyperaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
2 |
1 |
2 |
Conjunctival irritation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Conjunctival ulcer
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Conjunctivitis allergic
|
|
|
|
|
subjects affected / exposed
|
17 / 3576 (0.48%) |
15 / 3581 (0.42%) |
23 / 3576 (0.64%) |
23 / 3581 (0.64%) |
occurrences all number
|
17 |
15 |
23 |
23 |
Conjunctivochalasis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Corneal degeneration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Corneal leukoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Dacryostenosis acquired
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
4 |
2 |
4 |
Diabetic retinopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
3 |
1 |
Diplopia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
4 |
3 |
Dry age-related macular degeneration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Dry eye
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
15 / 3581 (0.42%) |
20 / 3576 (0.56%) |
24 / 3581 (0.67%) |
occurrences all number
|
11 |
15 |
21 |
24 |
Ectropion
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Entropion
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
3 |
0 |
Erythema of eyelid
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Exfoliation glaucoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Exophthalmos
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Eye allergy
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
1 |
5 |
2 |
Eye discharge
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Eye disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Eye haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
3 |
3 |
4 |
Eye inflammation
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
3 |
3 |
3 |
Eye irritation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
occurrences all number
|
1 |
1 |
4 |
5 |
Eye movement disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Eye pain
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
7 / 3581 (0.20%) |
8 / 3576 (0.22%) |
10 / 3581 (0.28%) |
occurrences all number
|
5 |
9 |
8 |
12 |
Eye pruritus
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
5 |
4 |
5 |
Eye swelling
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Eyelid disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Eyelid haematoma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Eyelid oedema
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
3 / 3576 (0.08%) |
7 / 3581 (0.20%) |
occurrences all number
|
2 |
4 |
3 |
7 |
Eyelid ptosis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
7 / 3576 (0.20%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
8 |
3 |
Eyelid rash
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Eyelids pruritus
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
3 |
0 |
Foreign body sensation in eyes
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
1 |
3 |
Glaucoma
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
18 / 3581 (0.50%) |
29 / 3576 (0.81%) |
40 / 3581 (1.12%) |
occurrences all number
|
8 |
18 |
29 |
42 |
Hypermetropia
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
3 |
0 |
3 |
0 |
Iritis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Keratitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
5 / 3581 (0.14%) |
occurrences all number
|
0 |
1 |
1 |
5 |
Keratopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Lacrimal disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Lacrimation increased
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
7 / 3581 (0.20%) |
9 / 3576 (0.25%) |
11 / 3581 (0.31%) |
occurrences all number
|
7 |
7 |
9 |
11 |
Lenticular opacities
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Macular degeneration
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
8 / 3581 (0.22%) |
13 / 3576 (0.36%) |
12 / 3581 (0.34%) |
occurrences all number
|
7 |
8 |
14 |
12 |
Macular fibrosis
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
1 |
4 |
2 |
Macular hole
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Macular oedema
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Maculopathy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Meibomian gland dysfunction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Mydriasis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Neovascular age-related macular degeneration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Ocular discomfort
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Ocular hyperaemia
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
6 / 3576 (0.17%) |
5 / 3581 (0.14%) |
occurrences all number
|
3 |
5 |
6 |
5 |
Open angle glaucoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Photopsia
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
1 |
4 |
1 |
Posterior capsule opacification
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Presbyopia
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
3 |
3 |
Pterygium
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
0 |
3 |
3 |
Refraction disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
4 |
1 |
4 |
Retinal degeneration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
2 |
1 |
Retinal detachment
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
1 |
1 |
5 |
Retinal disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
2 |
1 |
3 |
Retinal dystrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Retinal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
1 |
2 |
Retinal tear
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
2 |
2 |
Retinal vascular disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Retinal vascular thrombosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Retinal vein occlusion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Retinal vein thrombosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
2 |
2 |
Retinopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Retinopathy hypertensive
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
4 |
1 |
Scleral haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Strabismus
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
1 |
0 |
3 |
Sudden visual loss
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Trichiasis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Uveitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Vision blurred
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
8 / 3581 (0.22%) |
19 / 3576 (0.53%) |
13 / 3581 (0.36%) |
occurrences all number
|
14 |
8 |
20 |
14 |
Visual acuity reduced
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
8 / 3581 (0.22%) |
14 / 3576 (0.39%) |
12 / 3581 (0.34%) |
occurrences all number
|
9 |
8 |
14 |
12 |
Visual acuity reduced transiently
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Visual impairment
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
4 / 3581 (0.11%) |
11 / 3576 (0.31%) |
8 / 3581 (0.22%) |
occurrences all number
|
8 |
4 |
12 |
8 |
Vitreous degeneration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Vitreous detachment
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
3 |
4 |
5 |
Vitreous disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Vitreous floaters
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
7 / 3576 (0.20%) |
6 / 3581 (0.17%) |
occurrences all number
|
5 |
4 |
7 |
6 |
Vitreous haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Xerophthalmia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
2 |
2 |
Gastrointestinal disorders
|
|
|
|
|
Abdominal adhesions
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Abdominal discomfort
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
5 / 3581 (0.14%) |
16 / 3576 (0.45%) |
13 / 3581 (0.36%) |
occurrences all number
|
12 |
6 |
18 |
14 |
Abdominal distension
|
|
|
|
|
subjects affected / exposed
|
28 / 3576 (0.78%) |
27 / 3581 (0.75%) |
36 / 3576 (1.01%) |
40 / 3581 (1.12%) |
occurrences all number
|
32 |
29 |
43 |
44 |
Abdominal hernia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
3 |
2 |
4 |
Abdominal incarcerated hernia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Abdominal mass
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
2 |
2 |
Abdominal pain
|
|
|
|
|
subjects affected / exposed
|
75 / 3576 (2.10%) |
60 / 3581 (1.68%) |
114 / 3576 (3.19%) |
89 / 3581 (2.49%) |
occurrences all number
|
82 |
66 |
127 |
107 |
Abdominal pain lower
|
|
|
|
|
subjects affected / exposed
|
15 / 3576 (0.42%) |
7 / 3581 (0.20%) |
21 / 3576 (0.59%) |
14 / 3581 (0.39%) |
occurrences all number
|
16 |
7 |
22 |
14 |
Abdominal pain upper
|
|
|
|
|
subjects affected / exposed
|
96 / 3576 (2.68%) |
88 / 3581 (2.46%) |
124 / 3576 (3.47%) |
123 / 3581 (3.43%) |
occurrences all number
|
103 |
95 |
137 |
135 |
Abdominal tenderness
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
0 |
3 |
2 |
Abnormal faeces
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Acid peptic disease
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
1 |
3 |
4 |
Amalgam tattoo
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Anal fissure
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Anal fistula
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Anal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Anal incontinence
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
6 / 3576 (0.17%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
0 |
6 |
1 |
Anal prolapse
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
1 |
2 |
Anal pruritus
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
occurrences all number
|
4 |
1 |
7 |
2 |
Anorectal discomfort
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Anorectal disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Anorectal varices
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Aphthous ulcer
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
6 / 3581 (0.17%) |
6 / 3576 (0.17%) |
9 / 3581 (0.25%) |
occurrences all number
|
4 |
7 |
6 |
11 |
Ascites
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Barrett's oesophagus
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Bowel movement irregularity
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Breath odour
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Change of bowel habit
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Cheilitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Chronic gastritis
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
21 / 3581 (0.59%) |
33 / 3576 (0.92%) |
37 / 3581 (1.03%) |
occurrences all number
|
14 |
21 |
34 |
39 |
Coeliac disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
2 |
2 |
Colitis
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
8 / 3576 (0.22%) |
5 / 3581 (0.14%) |
occurrences all number
|
5 |
1 |
9 |
5 |
Colitis ischaemic
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Colitis microscopic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Colitis psychogenic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Colitis ulcerative
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Colon dysplasia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Constipation
|
|
|
|
|
subjects affected / exposed
|
162 / 3576 (4.53%) |
138 / 3581 (3.85%) |
210 / 3576 (5.87%) |
189 / 3581 (5.28%) |
occurrences all number
|
173 |
150 |
232 |
216 |
Crohn's disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Dental caries
|
|
|
|
|
subjects affected / exposed
|
50 / 3576 (1.40%) |
63 / 3581 (1.76%) |
99 / 3576 (2.77%) |
120 / 3581 (3.35%) |
occurrences all number
|
53 |
72 |
114 |
144 |
Dental cyst
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Dental necrosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Diaphragmatic hernia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Diarrhoea
|
|
|
|
|
subjects affected / exposed
|
133 / 3576 (3.72%) |
111 / 3581 (3.10%) |
191 / 3576 (5.34%) |
182 / 3581 (5.08%) |
occurrences all number
|
150 |
130 |
229 |
217 |
Diarrhoea haemorrhagic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
1 |
2 |
Diverticulum
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
11 / 3581 (0.31%) |
19 / 3576 (0.53%) |
16 / 3581 (0.45%) |
occurrences all number
|
11 |
12 |
19 |
18 |
Diverticulum intestinal
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
10 / 3581 (0.28%) |
20 / 3576 (0.56%) |
24 / 3581 (0.67%) |
occurrences all number
|
13 |
11 |
20 |
25 |
Diverticulum oesophageal
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Dry mouth
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
22 / 3581 (0.61%) |
20 / 3576 (0.56%) |
28 / 3581 (0.78%) |
occurrences all number
|
14 |
23 |
21 |
30 |
Duodenal polyp
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Duodenal ulcer
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Duodenitis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
3 |
2 |
4 |
Duodenogastric reflux
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
1 |
1 |
3 |
Dyspepsia
|
|
|
|
|
subjects affected / exposed
|
59 / 3576 (1.65%) |
70 / 3581 (1.95%) |
98 / 3576 (2.74%) |
122 / 3581 (3.41%) |
occurrences all number
|
65 |
79 |
107 |
136 |
Dysphagia
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
7 / 3576 (0.20%) |
6 / 3581 (0.17%) |
occurrences all number
|
5 |
4 |
9 |
7 |
Enamel anomaly
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Enteritis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Enterocolitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
0 |
3 |
Epigastric discomfort
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Erosive duodenitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
0 |
4 |
2 |
Erosive oesophagitis
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
2 |
3 |
2 |
Eructation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Faeces discoloured
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
2 |
1 |
2 |
Faeces hard
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
3 |
0 |
Faeces pale
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Femoral hernia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Flatulence
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
14 / 3581 (0.39%) |
19 / 3576 (0.53%) |
16 / 3581 (0.45%) |
occurrences all number
|
15 |
14 |
21 |
16 |
Food poisoning
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
10 / 3581 (0.28%) |
14 / 3576 (0.39%) |
13 / 3581 (0.36%) |
occurrences all number
|
12 |
11 |
16 |
14 |
Frequent bowel movements
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Functional gastrointestinal disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Gastric antral vascular ectasia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Gastric disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
5 / 3576 (0.14%) |
8 / 3581 (0.22%) |
occurrences all number
|
1 |
4 |
5 |
8 |
Gastric mucosa erythema
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Gastric mucosal hypertrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Gastric polyps
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
7 / 3581 (0.20%) |
13 / 3576 (0.36%) |
12 / 3581 (0.34%) |
occurrences all number
|
3 |
7 |
15 |
12 |
Gastric ulcer
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
1 / 3581 (0.03%) |
16 / 3576 (0.45%) |
5 / 3581 (0.14%) |
occurrences all number
|
9 |
1 |
16 |
5 |
Gastric xanthoma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Gastritis
|
|
|
|
|
subjects affected / exposed
|
102 / 3576 (2.85%) |
97 / 3581 (2.71%) |
166 / 3576 (4.64%) |
142 / 3581 (3.97%) |
occurrences all number
|
114 |
111 |
195 |
174 |
Gastritis erosive
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
10 / 3581 (0.28%) |
15 / 3576 (0.42%) |
19 / 3581 (0.53%) |
occurrences all number
|
7 |
10 |
15 |
19 |
Gastritis haemorrhagic
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Gastroduodenal ulcer
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Gastroduodenitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
2 |
3 |
2 |
Gastrointestinal angiodysplasia haemorrhagic
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Gastrointestinal disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
2 |
3 |
5 |
Gastrointestinal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
3 |
2 |
4 |
Gastrointestinal inflammation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
1 |
2 |
Gastrointestinal mucosal disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Gastrointestinal necrosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Gastrointestinal pain
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
2 |
3 |
3 |
Gastrointestinal sounds abnormal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Gastrooesophageal reflux disease
|
|
|
|
|
subjects affected / exposed
|
40 / 3576 (1.12%) |
40 / 3581 (1.12%) |
80 / 3576 (2.24%) |
78 / 3581 (2.18%) |
occurrences all number
|
43 |
44 |
86 |
84 |
Gastrooesophageal sphincter insufficiency
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
2 |
1 |
Gingival bleeding
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
5 |
3 |
5 |
Gingival disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
4 |
4 |
Gingival erosion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Gingival erythema
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Gingival hypertrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Gingival pain
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
9 / 3581 (0.25%) |
7 / 3576 (0.20%) |
14 / 3581 (0.39%) |
occurrences all number
|
7 |
9 |
7 |
15 |
Gingival recession
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Gingival swelling
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
3 |
3 |
4 |
Gingival ulceration
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Glossitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
3 |
3 |
3 |
Glossodynia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
0 / 3576 (0.00%) |
5 / 3581 (0.14%) |
occurrences all number
|
0 |
3 |
0 |
5 |
Haematemesis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Haematochezia
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
occurrences all number
|
4 |
4 |
5 |
5 |
Haemorrhagic erosive gastritis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Haemorrhoidal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
3 |
2 |
Haemorrhoids
|
|
|
|
|
subjects affected / exposed
|
30 / 3576 (0.84%) |
23 / 3581 (0.64%) |
51 / 3576 (1.43%) |
44 / 3581 (1.23%) |
occurrences all number
|
30 |
23 |
52 |
44 |
Hiatus hernia
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
14 / 3581 (0.39%) |
41 / 3576 (1.15%) |
35 / 3581 (0.98%) |
occurrences all number
|
20 |
14 |
41 |
35 |
Hyperchlorhydria
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
2 |
3 |
2 |
Ileal ulcer
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Ileus
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
3 |
0 |
3 |
Impaired gastric emptying
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Inflammatory bowel disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Inguinal hernia
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
8 / 3576 (0.22%) |
6 / 3581 (0.17%) |
occurrences all number
|
2 |
1 |
8 |
6 |
Intestinal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
1 |
1 |
4 |
Intestinal metaplasia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
3 |
1 |
Intestinal obstruction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Intestinal polyp
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
1 |
3 |
Intra-abdominal haematoma
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Intussusception
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Irritable bowel syndrome
|
|
|
|
|
subjects affected / exposed
|
26 / 3576 (0.73%) |
27 / 3581 (0.75%) |
47 / 3576 (1.31%) |
45 / 3581 (1.26%) |
occurrences all number
|
28 |
28 |
52 |
50 |
Large intestinal stenosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Large intestinal ulcer
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Large intestine polyp
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
9 / 3581 (0.25%) |
18 / 3576 (0.50%) |
24 / 3581 (0.67%) |
occurrences all number
|
10 |
9 |
18 |
24 |
Leukoplakia oral
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Lip haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Lip swelling
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Lip ulceration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Loose tooth
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
17 / 3581 (0.47%) |
21 / 3576 (0.59%) |
28 / 3581 (0.78%) |
occurrences all number
|
12 |
18 |
23 |
31 |
Lower gastrointestinal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
3 |
0 |
Lumbar hernia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Mallory-Weiss syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Megacolon
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Melaena
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Mouth cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Mouth swelling
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Mouth ulceration
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
3 / 3576 (0.08%) |
11 / 3581 (0.31%) |
occurrences all number
|
2 |
5 |
3 |
12 |
Mucous stools
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Nausea
|
|
|
|
|
subjects affected / exposed
|
57 / 3576 (1.59%) |
52 / 3581 (1.45%) |
68 / 3576 (1.90%) |
65 / 3581 (1.82%) |
occurrences all number
|
61 |
54 |
74 |
72 |
Noninfective gingivitis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
4 |
3 |
Odynophagia
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
8 / 3581 (0.22%) |
7 / 3576 (0.20%) |
8 / 3581 (0.22%) |
occurrences all number
|
8 |
8 |
8 |
8 |
Oesophageal achalasia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Oesophageal disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Oesophageal motility disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Oesophageal stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Oesophagitis
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
8 / 3576 (0.22%) |
14 / 3581 (0.39%) |
occurrences all number
|
3 |
5 |
8 |
14 |
Oral cavity fistula
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Oral contusion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Oral discomfort
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Oral disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Oral lichen planus
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Oral mucosa erosion
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Oral mucosal blistering
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Oral pain
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
occurrences all number
|
6 |
0 |
7 |
0 |
Pancreatic cyst
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
6 / 3581 (0.17%) |
occurrences all number
|
1 |
2 |
4 |
7 |
Pancreatic disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Pancreatic duct dilatation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Pancreatic fistula
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Pancreatic pseudocyst
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Pancreatic steatosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Pancreatitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Pancreatitis acute
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Pancreatitis chronic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Paraesthesia oral
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Parotid gland enlargement
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Peptic ulcer
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
3 |
4 |
5 |
Periodontal disease
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
5 / 3581 (0.14%) |
10 / 3576 (0.28%) |
9 / 3581 (0.25%) |
occurrences all number
|
6 |
5 |
11 |
9 |
Periodontal inflammation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Peritoneal lesion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Portal hypertensive gastropathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Proctalgia
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
0 |
5 |
2 |
Proctitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Rectal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
7 / 3576 (0.20%) |
6 / 3581 (0.17%) |
occurrences all number
|
5 |
2 |
7 |
6 |
Rectal polyp
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
2 |
2 |
Rectal prolapse
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Rectal tenesmus
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Reflux gastritis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Regurgitation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Salivary duct obstruction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Salivary gland enlargement
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Salivary hypersecretion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Sciatic hernia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Sensitivity of teeth
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
3 |
2 |
3 |
Stomatitis
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
8 / 3581 (0.22%) |
15 / 3576 (0.42%) |
11 / 3581 (0.31%) |
occurrences all number
|
11 |
10 |
17 |
14 |
Submaxillary gland enlargement
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Swollen tongue
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Tongue blistering
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Tongue discolouration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Tongue disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Tongue haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Tongue ulceration
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Tooth deposit
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Tooth discolouration
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Tooth disorder
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
9 / 3576 (0.25%) |
12 / 3581 (0.34%) |
occurrences all number
|
3 |
4 |
9 |
13 |
Tooth loss
|
|
|
|
|
subjects affected / exposed
|
27 / 3576 (0.76%) |
26 / 3581 (0.73%) |
55 / 3576 (1.54%) |
47 / 3581 (1.31%) |
occurrences all number
|
29 |
27 |
62 |
53 |
Toothache
|
|
|
|
|
subjects affected / exposed
|
33 / 3576 (0.92%) |
30 / 3581 (0.84%) |
48 / 3576 (1.34%) |
49 / 3581 (1.37%) |
occurrences all number
|
36 |
33 |
52 |
56 |
Umbilical hernia
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
6 / 3576 (0.17%) |
6 / 3581 (0.17%) |
occurrences all number
|
3 |
2 |
6 |
6 |
Upper gastrointestinal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
3 |
1 |
Varices oesophageal
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
2 |
3 |
Vomiting
|
|
|
|
|
subjects affected / exposed
|
49 / 3576 (1.37%) |
49 / 3581 (1.37%) |
61 / 3576 (1.71%) |
70 / 3581 (1.95%) |
occurrences all number
|
52 |
52 |
68 |
76 |
Skin and subcutaneous tissue disorders
|
|
|
|
|
Acne
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
2 |
Actinic keratosis
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
6 / 3581 (0.17%) |
11 / 3576 (0.31%) |
10 / 3581 (0.28%) |
occurrences all number
|
6 |
6 |
11 |
10 |
Alopecia
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
24 / 3581 (0.67%) |
24 / 3576 (0.67%) |
36 / 3581 (1.01%) |
occurrences all number
|
20 |
24 |
25 |
38 |
Alopecia areata
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Angiodermatitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Angioedema
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
6 |
0 |
6 |
1 |
Asteatosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
3 |
2 |
Blister
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
occurrences all number
|
6 |
1 |
7 |
2 |
Blister rupture
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Chronic pigmented purpura
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Cutis laxa
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Dandruff
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Decubitus ulcer
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
1 |
1 |
3 |
Dermal cyst
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
5 / 3581 (0.14%) |
6 / 3576 (0.17%) |
9 / 3581 (0.25%) |
occurrences all number
|
1 |
5 |
7 |
10 |
Dermatitis
|
|
|
|
|
subjects affected / exposed
|
30 / 3576 (0.84%) |
14 / 3581 (0.39%) |
47 / 3576 (1.31%) |
28 / 3581 (0.78%) |
occurrences all number
|
33 |
15 |
53 |
30 |
Dermatitis acneiform
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Dermatitis allergic
|
|
|
|
|
subjects affected / exposed
|
31 / 3576 (0.87%) |
24 / 3581 (0.67%) |
51 / 3576 (1.43%) |
40 / 3581 (1.12%) |
occurrences all number
|
32 |
27 |
56 |
45 |
Dermatitis atopic
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
0 / 3581 (0.00%) |
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
occurrences all number
|
5 |
0 |
6 |
3 |
Dermatitis bullous
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Dermatitis contact
|
|
|
|
|
subjects affected / exposed
|
15 / 3576 (0.42%) |
10 / 3581 (0.28%) |
22 / 3576 (0.62%) |
18 / 3581 (0.50%) |
occurrences all number
|
17 |
10 |
26 |
19 |
Diabetic dermopathy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Diabetic foot
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
1 |
1 |
3 |
Drug eruption
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
4 |
4 |
5 |
Dry skin
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
9 / 3581 (0.25%) |
14 / 3576 (0.39%) |
13 / 3581 (0.36%) |
occurrences all number
|
10 |
9 |
14 |
13 |
Dyshidrotic eczema
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Ecchymosis
|
|
|
|
|
subjects affected / exposed
|
28 / 3576 (0.78%) |
26 / 3581 (0.73%) |
42 / 3576 (1.17%) |
38 / 3581 (1.06%) |
occurrences all number
|
32 |
28 |
50 |
41 |
Eczema
|
|
|
|
|
subjects affected / exposed
|
27 / 3576 (0.76%) |
23 / 3581 (0.64%) |
51 / 3576 (1.43%) |
46 / 3581 (1.28%) |
occurrences all number
|
29 |
24 |
55 |
51 |
Eczema asteatotic
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
occurrences all number
|
5 |
1 |
8 |
1 |
Erythema
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
20 / 3581 (0.56%) |
19 / 3576 (0.53%) |
22 / 3581 (0.61%) |
occurrences all number
|
14 |
30 |
21 |
33 |
Erythema multiforme
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Exfoliative rash
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Generalised erythema
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Granuloma annulare
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
4 |
0 |
5 |
Haemorrhage subcutaneous
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
4 |
2 |
Hand dermatitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
3 |
1 |
Hirsutism
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hyperhidrosis
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
4 / 3581 (0.11%) |
13 / 3576 (0.36%) |
11 / 3581 (0.31%) |
occurrences all number
|
12 |
4 |
13 |
12 |
Hyperkeratosis
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
7 / 3581 (0.20%) |
8 / 3576 (0.22%) |
11 / 3581 (0.31%) |
occurrences all number
|
7 |
7 |
8 |
11 |
Hypertrophic scar
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Idiopathic urticaria
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Ingrowing nail
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
8 / 3581 (0.22%) |
occurrences all number
|
4 |
4 |
9 |
8 |
Intertrigo
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
2 |
3 |
4 |
Leukoplakia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Lichen planus
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
2 |
1 |
3 |
Lichen sclerosus
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
3 |
1 |
Lipohypertrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Macule
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
6 / 3576 (0.17%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
3 |
7 |
4 |
Mechanical urticaria
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Miliaria
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
3 |
3 |
5 |
Nail bed disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Nail bed inflammation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Nail discolouration
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
1 |
2 |
Nail disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
2 |
0 |
3 |
Nail hypertrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Nail psoriasis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Nail ridging
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
4 / 3581 (0.11%) |
0 / 3576 (0.00%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
4 |
0 |
4 |
Neurodermatitis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Night sweats
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
4 |
4 |
4 |
Onychoclasis
|
|
|
|
|
subjects affected / exposed
|
15 / 3576 (0.42%) |
4 / 3581 (0.11%) |
15 / 3576 (0.42%) |
4 / 3581 (0.11%) |
occurrences all number
|
15 |
4 |
15 |
5 |
Onycholysis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
3 |
0 |
3 |
Onychomadesis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Onychomalacia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Pain of skin
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Palmoplantar keratoderma
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Panniculitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Papule
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
occurrences all number
|
5 |
3 |
5 |
4 |
Peau d'orange
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
4 |
0 |
Petechiae
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Photosensitivity reaction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Pigmentation disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Pityriasis rosea
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Pruritus
|
|
|
|
|
subjects affected / exposed
|
47 / 3576 (1.31%) |
45 / 3581 (1.26%) |
66 / 3576 (1.85%) |
54 / 3581 (1.51%) |
occurrences all number
|
49 |
53 |
71 |
63 |
Pruritus allergic
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
6 / 3576 (0.17%) |
1 / 3581 (0.03%) |
occurrences all number
|
7 |
1 |
8 |
1 |
Pruritus generalised
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
17 / 3581 (0.47%) |
27 / 3576 (0.76%) |
22 / 3581 (0.61%) |
occurrences all number
|
22 |
20 |
31 |
25 |
Psoriasis
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
6 / 3581 (0.17%) |
12 / 3576 (0.34%) |
8 / 3581 (0.22%) |
occurrences all number
|
8 |
7 |
15 |
11 |
Purpura
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Rash
|
|
|
|
|
subjects affected / exposed
|
31 / 3576 (0.87%) |
38 / 3581 (1.06%) |
53 / 3576 (1.48%) |
57 / 3581 (1.59%) |
occurrences all number
|
37 |
44 |
61 |
68 |
Rash erythematous
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
4 / 3581 (0.11%) |
0 / 3576 (0.00%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
5 |
0 |
5 |
Rash generalised
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
5 / 3581 (0.14%) |
0 / 3576 (0.00%) |
7 / 3581 (0.20%) |
occurrences all number
|
0 |
5 |
0 |
7 |
Rash macular
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
3 |
1 |
3 |
Rash maculo-papular
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Rash papular
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
3 |
1 |
4 |
Rash pruritic
|
|
|
|
|
subjects affected / exposed
|
15 / 3576 (0.42%) |
11 / 3581 (0.31%) |
18 / 3576 (0.50%) |
17 / 3581 (0.47%) |
occurrences all number
|
16 |
12 |
22 |
19 |
Rosacea
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
1 |
3 |
3 |
Scab
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Scar pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Seborrhoeic dermatitis
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
7 / 3581 (0.20%) |
5 / 3576 (0.14%) |
8 / 3581 (0.22%) |
occurrences all number
|
3 |
8 |
5 |
10 |
Skin atrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Skin burning sensation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Skin discolouration
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
4 |
0 |
Skin disorder
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
7 / 3581 (0.20%) |
6 / 3576 (0.17%) |
7 / 3581 (0.20%) |
occurrences all number
|
5 |
7 |
7 |
7 |
Skin erosion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Skin exfoliation
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
4 |
1 |
5 |
1 |
Skin fissures
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
3 |
2 |
Skin haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Skin hyperpigmentation
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
0 |
4 |
1 |
Skin hypertrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Skin induration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Skin irritation
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
3 |
1 |
3 |
3 |
Skin lesion
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
12 / 3581 (0.34%) |
27 / 3576 (0.76%) |
22 / 3581 (0.61%) |
occurrences all number
|
20 |
13 |
28 |
23 |
Skin mass
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
occurrences all number
|
4 |
0 |
5 |
1 |
Skin plaque
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Skin swelling
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Skin ulcer
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
11 / 3581 (0.31%) |
occurrences all number
|
7 |
4 |
10 |
12 |
Skin ulcer haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Skin warm
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Solar dermatitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Solar lentigo
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
2 |
2 |
Stasis dermatitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Subcutaneous emphysema
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Sweat gland disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Swelling face
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Telangiectasia
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Transient acantholytic dermatosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Trichorrhexis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Urticaria
|
|
|
|
|
subjects affected / exposed
|
22 / 3576 (0.62%) |
18 / 3581 (0.50%) |
29 / 3576 (0.81%) |
27 / 3581 (0.75%) |
occurrences all number
|
23 |
22 |
31 |
33 |
Urticaria chronic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Vascular purpura
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Vascular skin disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Vitiligo
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
2 |
2 |
Xeroderma
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
7 / 3581 (0.20%) |
12 / 3576 (0.34%) |
12 / 3581 (0.34%) |
occurrences all number
|
5 |
8 |
12 |
13 |
Renal and urinary disorders
|
|
|
|
|
Acute kidney injury
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
2 |
4 |
4 |
Azotaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Bladder disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Bladder diverticulum
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Bladder dysfunction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Bladder pain
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Bladder prolapse
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
4 / 3581 (0.11%) |
0 / 3576 (0.00%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
4 |
0 |
4 |
Bladder spasm
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
3 |
2 |
Calculus bladder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Calculus urinary
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
5 |
0 |
Choluria
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Chromaturia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
3 |
0 |
4 |
Chronic kidney disease
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
19 / 3581 (0.53%) |
30 / 3576 (0.84%) |
34 / 3581 (0.95%) |
occurrences all number
|
13 |
20 |
31 |
36 |
Cystitis haemorrhagic
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
2 |
3 |
Cystitis interstitial
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Cystitis noninfective
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
1 |
4 |
2 |
Diabetic nephropathy
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
3 |
4 |
4 |
Dysuria
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
16 / 3581 (0.45%) |
23 / 3576 (0.64%) |
24 / 3581 (0.67%) |
occurrences all number
|
10 |
17 |
24 |
27 |
Haematuria
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
7 / 3581 (0.20%) |
11 / 3576 (0.31%) |
12 / 3581 (0.34%) |
occurrences all number
|
5 |
8 |
13 |
14 |
Hydrocalyx
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hydronephrosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
1 |
0 |
4 |
Hypercalciuria
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hypertensive nephropathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
1 |
2 |
Hypertonic bladder
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
6 / 3576 (0.17%) |
9 / 3581 (0.25%) |
occurrences all number
|
3 |
5 |
7 |
9 |
Incontinence
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
3 |
2 |
4 |
Kidney enlargement
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Kidney fibrosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Leukocyturia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
1 |
3 |
Microalbuminuria
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Micturition disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Micturition urgency
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
3 |
3 |
Nephrocalcinosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Nephrolithiasis
|
|
|
|
|
subjects affected / exposed
|
15 / 3576 (0.42%) |
17 / 3581 (0.47%) |
30 / 3576 (0.84%) |
33 / 3581 (0.92%) |
occurrences all number
|
15 |
17 |
31 |
33 |
Nephropathy
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
occurrences all number
|
3 |
0 |
3 |
5 |
Nephrosclerosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Neurogenic bladder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Nocturia
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
3 |
3 |
3 |
4 |
Pollakiuria
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
6 / 3581 (0.17%) |
17 / 3576 (0.48%) |
9 / 3581 (0.25%) |
occurrences all number
|
9 |
8 |
17 |
11 |
Polyuria
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
occurrences all number
|
4 |
2 |
5 |
2 |
Proteinuria
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
occurrences all number
|
4 |
1 |
6 |
2 |
Pyelocaliectasis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
2 |
2 |
4 |
Renal artery stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Renal atrophy
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
2 |
3 |
4 |
Renal colic
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
2 |
4 |
4 |
Renal cyst
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
23 / 3581 (0.64%) |
39 / 3576 (1.09%) |
44 / 3581 (1.23%) |
occurrences all number
|
12 |
24 |
41 |
46 |
Renal disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
2 |
2 |
Renal failure
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
8 / 3581 (0.22%) |
16 / 3576 (0.45%) |
12 / 3581 (0.34%) |
occurrences all number
|
6 |
8 |
18 |
13 |
Renal impairment
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
9 / 3581 (0.25%) |
23 / 3576 (0.64%) |
23 / 3581 (0.64%) |
occurrences all number
|
14 |
9 |
23 |
24 |
Renal lipomatosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Renal mass
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Renal pain
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
2 |
3 |
Stress urinary incontinence
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
4 |
1 |
Ureteric dilatation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Ureteric stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Ureterolithiasis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Urethral caruncle
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Urethral pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Urethral stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Urethral syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Urge incontinence
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
1 |
2 |
Urinary hesitation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Urinary incontinence
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
15 / 3581 (0.42%) |
28 / 3576 (0.78%) |
29 / 3581 (0.81%) |
occurrences all number
|
14 |
16 |
28 |
30 |
Urinary retention
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
1 |
3 |
5 |
Urinary tract disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Urinary tract inflammation
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Urine flow decreased
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Urine odour abnormal
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
3 |
1 |
Urogenital haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Endocrine disorders
|
|
|
|
|
Adrenal disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Adrenal insufficiency
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Adrenal mass
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
1 |
2 |
Autoimmune thyroiditis
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
6 / 3576 (0.17%) |
6 / 3581 (0.17%) |
occurrences all number
|
4 |
1 |
6 |
6 |
Endocrine disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Goitre
|
|
|
|
|
subjects affected / exposed
|
17 / 3576 (0.48%) |
16 / 3581 (0.45%) |
41 / 3576 (1.15%) |
33 / 3581 (0.92%) |
occurrences all number
|
17 |
17 |
42 |
34 |
Haemorrhagic thyroid cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Hyperparathyroidism
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
1 |
3 |
4 |
Hyperparathyroidism secondary
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Hyperthyroidism
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
6 / 3576 (0.17%) |
10 / 3581 (0.28%) |
occurrences all number
|
2 |
5 |
6 |
10 |
Hypoparathyroidism
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hypothyroidic goitre
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Hypothyroidism
|
|
|
|
|
subjects affected / exposed
|
40 / 3576 (1.12%) |
41 / 3581 (1.14%) |
74 / 3576 (2.07%) |
79 / 3581 (2.21%) |
occurrences all number
|
41 |
41 |
79 |
81 |
Inappropriate antidiuretic hormone secretion
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Myxoedema
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Primary hypothyroidism
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
2 |
1 |
Secondary hypothyroidism
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Thyroid atrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Thyroid cyst
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
1 |
5 |
1 |
Thyroid disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
3 |
1 |
Thyroid mass
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
9 / 3576 (0.25%) |
8 / 3581 (0.22%) |
occurrences all number
|
5 |
2 |
10 |
10 |
Thyroiditis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Thyroiditis chronic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Thyroiditis subacute
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Musculoskeletal and connective tissue disorders
|
|
|
|
|
Ankle deformity
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Arthralgia
|
|
|
|
|
subjects affected / exposed
|
434 / 3576 (12.14%) |
468 / 3581 (13.07%) |
663 / 3576 (18.54%) |
668 / 3581 (18.65%) |
occurrences all number
|
532 |
594 |
882 |
928 |
Arthritis
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
19 / 3581 (0.53%) |
18 / 3576 (0.50%) |
30 / 3581 (0.84%) |
occurrences all number
|
12 |
20 |
21 |
31 |
Arthritis reactive
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Arthropathy
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
1 |
5 |
4 |
Back pain
|
|
|
|
|
subjects affected / exposed
|
380 / 3576 (10.63%) |
373 / 3581 (10.42%) |
573 / 3576 (16.02%) |
518 / 3581 (14.47%) |
occurrences all number
|
431 |
434 |
707 |
649 |
Bone atrophy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Bone cyst
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
3 |
1 |
Bone deformity
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Bone disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
1 |
2 |
Bone infarction
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Bone loss
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
2 |
2 |
Bone pain
|
|
|
|
|
subjects affected / exposed
|
47 / 3576 (1.31%) |
55 / 3581 (1.54%) |
62 / 3576 (1.73%) |
72 / 3581 (2.01%) |
occurrences all number
|
60 |
67 |
78 |
87 |
Bursitis
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
19 / 3581 (0.53%) |
21 / 3576 (0.59%) |
33 / 3581 (0.92%) |
occurrences all number
|
13 |
20 |
22 |
36 |
Cervical spinal stenosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
2 |
2 |
Chondritis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Chondrocalcinosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Chondrocalcinosis pyrophosphate
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Chondrolysis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Chondromalacia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Chondropathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
occurrences all number
|
0 |
1 |
2 |
5 |
Coccydynia
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
6 / 3576 (0.17%) |
7 / 3581 (0.20%) |
occurrences all number
|
4 |
2 |
6 |
7 |
Costochondritis
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
8 / 3581 (0.22%) |
25 / 3576 (0.70%) |
16 / 3581 (0.45%) |
occurrences all number
|
14 |
9 |
26 |
17 |
Crystal arthropathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Deformity thorax
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Dupuytren's contracture
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
2 |
2 |
Enthesopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
occurrences all number
|
0 |
2 |
2 |
5 |
Exostosis
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
6 / 3581 (0.17%) |
26 / 3576 (0.73%) |
18 / 3581 (0.50%) |
occurrences all number
|
14 |
7 |
28 |
20 |
Extremity contracture
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Facial asymmetry
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Fasciitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
1 |
2 |
Fibromyalgia
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
5 / 3581 (0.14%) |
11 / 3576 (0.31%) |
7 / 3581 (0.20%) |
occurrences all number
|
10 |
5 |
11 |
7 |
Finger deformity
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Fistula
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Flank pain
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
12 / 3581 (0.34%) |
9 / 3576 (0.25%) |
13 / 3581 (0.36%) |
occurrences all number
|
4 |
12 |
9 |
14 |
Foot deformity
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
9 / 3581 (0.25%) |
15 / 3576 (0.42%) |
14 / 3581 (0.39%) |
occurrences all number
|
9 |
10 |
17 |
15 |
Fracture delayed union
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Fracture pain
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
occurrences all number
|
5 |
5 |
5 |
5 |
Gouty arthritis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Groin pain
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
14 / 3581 (0.39%) |
17 / 3576 (0.48%) |
19 / 3581 (0.53%) |
occurrences all number
|
11 |
14 |
20 |
19 |
Interspinous osteoarthritis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Intervertebral disc compression
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Intervertebral disc degeneration
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
7 / 3576 (0.20%) |
5 / 3581 (0.14%) |
occurrences all number
|
1 |
2 |
7 |
6 |
Intervertebral disc disorder
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
16 / 3581 (0.45%) |
22 / 3576 (0.62%) |
28 / 3581 (0.78%) |
occurrences all number
|
13 |
16 |
26 |
28 |
Intervertebral disc displacement
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Intervertebral disc protrusion
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
8 / 3581 (0.22%) |
24 / 3576 (0.67%) |
16 / 3581 (0.45%) |
occurrences all number
|
14 |
8 |
29 |
17 |
Intervertebral disc space narrowing
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
1 |
1 |
3 |
Jaw cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Joint contracture
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
2 |
4 |
2 |
Joint crepitation
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
occurrences all number
|
3 |
1 |
4 |
1 |
Joint effusion
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
4 |
3 |
Joint hyperextension
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Joint lock
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Joint range of motion decreased
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
10 / 3576 (0.28%) |
3 / 3581 (0.08%) |
occurrences all number
|
6 |
3 |
10 |
3 |
Joint stiffness
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
4 / 3576 (0.11%) |
7 / 3581 (0.20%) |
occurrences all number
|
3 |
5 |
5 |
7 |
Joint swelling
|
|
|
|
|
subjects affected / exposed
|
21 / 3576 (0.59%) |
16 / 3581 (0.45%) |
29 / 3576 (0.81%) |
26 / 3581 (0.73%) |
occurrences all number
|
23 |
18 |
31 |
28 |
Joint warmth
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Kyphosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
8 / 3576 (0.22%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
8 |
2 |
Ligamentitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Limb asymmetry
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Limb discomfort
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
3 |
2 |
4 |
Limb mass
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
3 |
0 |
Lordosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
2 |
2 |
4 |
Low turnover osteopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Lumbar spinal stenosis
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
8 / 3581 (0.22%) |
11 / 3576 (0.31%) |
15 / 3581 (0.42%) |
occurrences all number
|
6 |
8 |
12 |
15 |
Mastication disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Meniscal degeneration
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Metatarsalgia
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
3 / 3581 (0.08%) |
11 / 3576 (0.31%) |
3 / 3581 (0.08%) |
occurrences all number
|
8 |
3 |
12 |
3 |
Mobility decreased
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Monarthritis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Muscle atrophy
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
3 |
1 |
Muscle contracture
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
21 / 3581 (0.59%) |
24 / 3576 (0.67%) |
25 / 3581 (0.70%) |
occurrences all number
|
23 |
23 |
27 |
27 |
Muscle fatigue
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
2 / 3581 (0.06%) |
8 / 3576 (0.22%) |
3 / 3581 (0.08%) |
occurrences all number
|
8 |
2 |
8 |
3 |
Muscle haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Muscle spasms
|
|
|
|
|
subjects affected / exposed
|
140 / 3576 (3.91%) |
163 / 3581 (4.55%) |
201 / 3576 (5.62%) |
211 / 3581 (5.89%) |
occurrences all number
|
155 |
179 |
236 |
246 |
Muscle tightness
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
5 |
1 |
Muscle twitching
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Muscular weakness
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
19 / 3581 (0.53%) |
32 / 3576 (0.89%) |
29 / 3581 (0.81%) |
occurrences all number
|
22 |
21 |
34 |
31 |
Musculoskeletal chest pain
|
|
|
|
|
subjects affected / exposed
|
21 / 3576 (0.59%) |
14 / 3581 (0.39%) |
37 / 3576 (1.03%) |
28 / 3581 (0.78%) |
occurrences all number
|
21 |
14 |
38 |
29 |
Musculoskeletal discomfort
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
3 / 3576 (0.08%) |
7 / 3581 (0.20%) |
occurrences all number
|
2 |
5 |
3 |
7 |
Musculoskeletal disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Musculoskeletal pain
|
|
|
|
|
subjects affected / exposed
|
172 / 3576 (4.81%) |
168 / 3581 (4.69%) |
260 / 3576 (7.27%) |
263 / 3581 (7.34%) |
occurrences all number
|
188 |
182 |
301 |
304 |
Musculoskeletal stiffness
|
|
|
|
|
subjects affected / exposed
|
16 / 3576 (0.45%) |
18 / 3581 (0.50%) |
20 / 3576 (0.56%) |
20 / 3581 (0.56%) |
occurrences all number
|
17 |
19 |
22 |
22 |
Myalgia
|
|
|
|
|
subjects affected / exposed
|
127 / 3576 (3.55%) |
114 / 3581 (3.18%) |
175 / 3576 (4.89%) |
159 / 3581 (4.44%) |
occurrences all number
|
150 |
129 |
206 |
181 |
Myofascial pain syndrome
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
4 |
1 |
4 |
5 |
Myofascitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Myositis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Myositis ossificans
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Neck deformity
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Neck pain
|
|
|
|
|
subjects affected / exposed
|
54 / 3576 (1.51%) |
80 / 3581 (2.23%) |
83 / 3576 (2.32%) |
116 / 3581 (3.24%) |
occurrences all number
|
61 |
85 |
93 |
127 |
Nodal osteoarthritis
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
3 / 3581 (0.08%) |
9 / 3576 (0.25%) |
6 / 3581 (0.17%) |
occurrences all number
|
7 |
3 |
9 |
6 |
Osteitis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
0 |
5 |
3 |
Osteoarthritis
|
|
|
|
|
subjects affected / exposed
|
210 / 3576 (5.87%) |
184 / 3581 (5.14%) |
329 / 3576 (9.20%) |
321 / 3581 (8.96%) |
occurrences all number
|
235 |
221 |
381 |
398 |
Osteochondritis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Osteochondrosis
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
5 / 3581 (0.14%) |
10 / 3576 (0.28%) |
10 / 3581 (0.28%) |
occurrences all number
|
6 |
5 |
12 |
10 |
Osteolysis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Osteonecrosis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
4 |
4 |
Osteopenia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Osteoporosis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
9 / 3576 (0.25%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
9 |
2 |
Osteosclerosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
5 / 3581 (0.14%) |
occurrences all number
|
0 |
2 |
1 |
8 |
Pain in extremity
|
|
|
|
|
subjects affected / exposed
|
299 / 3576 (8.36%) |
278 / 3581 (7.76%) |
407 / 3576 (11.38%) |
417 / 3581 (11.64%) |
occurrences all number
|
356 |
353 |
510 |
536 |
Pain in jaw
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
8 / 3581 (0.22%) |
5 / 3576 (0.14%) |
8 / 3581 (0.22%) |
occurrences all number
|
1 |
8 |
5 |
9 |
Palindromic rheumatism
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Patellofemoral pain syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
1 |
2 |
Periarthritis
|
|
|
|
|
subjects affected / exposed
|
19 / 3576 (0.53%) |
10 / 3581 (0.28%) |
31 / 3576 (0.87%) |
25 / 3581 (0.70%) |
occurrences all number
|
20 |
10 |
35 |
27 |
Periostitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
3 |
2 |
3 |
Peripheral arthritis
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
0 |
4 |
2 |
Plantar fasciitis
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
10 / 3581 (0.28%) |
10 / 3576 (0.28%) |
18 / 3581 (0.50%) |
occurrences all number
|
5 |
10 |
10 |
18 |
Polyarthritis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
5 |
2 |
Polymyalgia rheumatica
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
7 |
3 |
Rheumatic disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Rheumatoid arthritis
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
0 / 3581 (0.00%) |
8 / 3576 (0.22%) |
7 / 3581 (0.20%) |
occurrences all number
|
4 |
0 |
8 |
7 |
Rib deformity
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Rotator cuff syndrome
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
9 / 3581 (0.25%) |
22 / 3576 (0.62%) |
18 / 3581 (0.50%) |
occurrences all number
|
12 |
9 |
22 |
18 |
Sacroiliitis
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
occurrences all number
|
4 |
2 |
6 |
4 |
Sarcopenia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Scoliosis
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
8 / 3581 (0.22%) |
18 / 3576 (0.50%) |
17 / 3581 (0.47%) |
occurrences all number
|
8 |
9 |
18 |
18 |
Senile ankylosing vertebral hyperostosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Seronegative arthritis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Sinus tarsi syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Sjogren's syndrome
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
3 |
3 |
5 |
Spinal column stenosis
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
8 / 3576 (0.22%) |
6 / 3581 (0.17%) |
occurrences all number
|
6 |
2 |
9 |
6 |
Spinal deformity
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
3 |
2 |
Spinal disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Spinal flattening
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Spinal osteoarthritis
|
|
|
|
|
subjects affected / exposed
|
86 / 3576 (2.40%) |
86 / 3581 (2.40%) |
138 / 3576 (3.86%) |
137 / 3581 (3.83%) |
occurrences all number
|
105 |
105 |
183 |
188 |
Spinal pain
|
|
|
|
|
subjects affected / exposed
|
42 / 3576 (1.17%) |
33 / 3581 (0.92%) |
57 / 3576 (1.59%) |
62 / 3581 (1.73%) |
occurrences all number
|
43 |
37 |
62 |
68 |
Spondylitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
1 |
2 |
Spondylolisthesis
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
7 / 3581 (0.20%) |
10 / 3576 (0.28%) |
16 / 3581 (0.45%) |
occurrences all number
|
6 |
7 |
11 |
16 |
Spondylolysis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Sympathetic posterior cervical syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Synovial cyst
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
13 / 3581 (0.36%) |
22 / 3576 (0.62%) |
28 / 3581 (0.78%) |
occurrences all number
|
12 |
13 |
23 |
29 |
Synovitis
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
7 / 3576 (0.20%) |
3 / 3581 (0.08%) |
occurrences all number
|
3 |
0 |
7 |
3 |
Systemic lupus erythematosus
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Temporomandibular joint syndrome
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
5 / 3581 (0.14%) |
10 / 3576 (0.28%) |
7 / 3581 (0.20%) |
occurrences all number
|
8 |
5 |
12 |
7 |
Tendinous contracture
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Tendon disorder
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
7 / 3576 (0.20%) |
8 / 3581 (0.22%) |
occurrences all number
|
6 |
2 |
7 |
8 |
Tendon pain
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
2 |
1 |
Tendonitis
|
|
|
|
|
subjects affected / exposed
|
20 / 3576 (0.56%) |
28 / 3581 (0.78%) |
37 / 3576 (1.03%) |
44 / 3581 (1.23%) |
occurrences all number
|
20 |
28 |
39 |
45 |
Tenosynovitis
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
8 / 3581 (0.22%) |
16 / 3576 (0.45%) |
16 / 3581 (0.45%) |
occurrences all number
|
8 |
9 |
17 |
18 |
Tenosynovitis stenosans
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
7 / 3581 (0.20%) |
9 / 3576 (0.25%) |
10 / 3581 (0.28%) |
occurrences all number
|
8 |
7 |
9 |
10 |
Torticollis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Trigger finger
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
14 / 3581 (0.39%) |
26 / 3576 (0.73%) |
25 / 3581 (0.70%) |
occurrences all number
|
14 |
15 |
27 |
27 |
Vertebral foraminal stenosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
4 |
1 |
Vertebral osteophyte
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Vertebral wedging
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Wrist deformity
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Infections and infestations
|
|
|
|
|
Abdominal infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Abscess
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Abscess bacterial
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Abscess jaw
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Abscess limb
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
occurrences all number
|
4 |
3 |
5 |
3 |
Abscess neck
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Abscess of eyelid
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Abscess oral
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Abscess rupture
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Acarodermatitis
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
6 / 3576 (0.17%) |
5 / 3581 (0.14%) |
occurrences all number
|
4 |
3 |
7 |
5 |
Actinomycotic pulmonary infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Acute sinusitis
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
4 / 3576 (0.11%) |
9 / 3581 (0.25%) |
occurrences all number
|
3 |
6 |
4 |
12 |
Alphaviral infection
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Amoebiasis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
occurrences all number
|
1 |
2 |
3 |
5 |
Amoebic dysentery
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
2 / 3576 (0.06%) |
6 / 3581 (0.17%) |
occurrences all number
|
2 |
5 |
2 |
6 |
Anal abscess
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Angular cheilitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
3 |
1 |
3 |
Appendicitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Arthritis bacterial
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Ascariasis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Asymptomatic bacteriuria
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
7 / 3576 (0.20%) |
9 / 3581 (0.25%) |
occurrences all number
|
2 |
4 |
7 |
9 |
Atypical pneumonia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Bacteraemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Bacterial diarrhoea
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
2 |
4 |
2 |
Bacterial infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Bacterial rhinitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Bacterial vaginosis
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
7 / 3581 (0.20%) |
4 / 3576 (0.11%) |
9 / 3581 (0.25%) |
occurrences all number
|
3 |
7 |
4 |
9 |
Bacteriuria
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
1 |
2 |
Beta haemolytic streptococcal infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Blastocystis infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Body tinea
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
1 |
2 |
Borrelia infection
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
0 |
1 |
2 |
Bronchiolitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
3 |
3 |
Bronchitis
|
|
|
|
|
subjects affected / exposed
|
90 / 3576 (2.52%) |
80 / 3581 (2.23%) |
162 / 3576 (4.53%) |
173 / 3581 (4.83%) |
occurrences all number
|
97 |
83 |
196 |
205 |
Bronchitis bacterial
|
|
|
|
|
subjects affected / exposed
|
21 / 3576 (0.59%) |
12 / 3581 (0.34%) |
24 / 3576 (0.67%) |
15 / 3581 (0.42%) |
occurrences all number
|
22 |
14 |
28 |
17 |
Bronchitis viral
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
9 / 3576 (0.25%) |
4 / 3581 (0.11%) |
occurrences all number
|
6 |
3 |
9 |
4 |
Bronchopulmonary aspergillosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Campylobacter gastroenteritis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Candida infection
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
0 |
1 |
2 |
Cellulitis
|
|
|
|
|
subjects affected / exposed
|
16 / 3576 (0.45%) |
13 / 3581 (0.36%) |
24 / 3576 (0.67%) |
27 / 3581 (0.75%) |
occurrences all number
|
16 |
13 |
24 |
30 |
Chikungunya virus infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
2 |
2 |
Cholecystitis infective
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Chronic hepatitis C
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Chronic sinusitis
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
11 / 3576 (0.31%) |
6 / 3581 (0.17%) |
occurrences all number
|
5 |
2 |
11 |
7 |
Chronic tonsillitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Clostridial infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Clostridium difficile infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Conjunctivitis
|
|
|
|
|
subjects affected / exposed
|
24 / 3576 (0.67%) |
34 / 3581 (0.95%) |
42 / 3576 (1.17%) |
54 / 3581 (1.51%) |
occurrences all number
|
25 |
36 |
43 |
57 |
Conjunctivitis bacterial
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
11 / 3581 (0.31%) |
9 / 3576 (0.25%) |
14 / 3581 (0.39%) |
occurrences all number
|
8 |
11 |
9 |
14 |
Conjunctivitis viral
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
1 |
3 |
Cystitis
|
|
|
|
|
subjects affected / exposed
|
49 / 3576 (1.37%) |
56 / 3581 (1.56%) |
84 / 3576 (2.35%) |
84 / 3581 (2.35%) |
occurrences all number
|
61 |
62 |
114 |
100 |
Cystitis bacterial
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
7 / 3581 (0.20%) |
9 / 3576 (0.25%) |
8 / 3581 (0.22%) |
occurrences all number
|
8 |
12 |
10 |
19 |
Cystitis escherichia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Cystitis klebsiella
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Cystitis viral
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Dacryocystitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Dengue fever
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
7 / 3576 (0.20%) |
6 / 3581 (0.17%) |
occurrences all number
|
0 |
0 |
8 |
6 |
Dental fistula
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Dental gangrene
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Dermatitis infected
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Dermatophytosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Dermatophytosis of nail
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
1 |
1 |
4 |
Diarrhoea infectious
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
7 / 3581 (0.20%) |
3 / 3576 (0.08%) |
8 / 3581 (0.22%) |
occurrences all number
|
3 |
7 |
3 |
8 |
Diverticulitis
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
6 / 3581 (0.17%) |
9 / 3576 (0.25%) |
8 / 3581 (0.22%) |
occurrences all number
|
4 |
6 |
9 |
9 |
Dysentery
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Ear infection
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
8 / 3581 (0.22%) |
16 / 3576 (0.45%) |
17 / 3581 (0.47%) |
occurrences all number
|
13 |
8 |
16 |
18 |
Ear infection bacterial
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
2 |
2 |
Ear infection viral
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Eczema impetiginous
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Eczema infected
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Enteritis infectious
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Enterobiasis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Enterocolitis infectious
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Erysipelas
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
5 / 3581 (0.14%) |
14 / 3576 (0.39%) |
9 / 3581 (0.25%) |
occurrences all number
|
7 |
5 |
15 |
10 |
Erythema migrans
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
3 |
1 |
4 |
Escherichia urinary tract infection
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
5 / 3581 (0.14%) |
12 / 3576 (0.34%) |
5 / 3581 (0.14%) |
occurrences all number
|
8 |
5 |
13 |
5 |
Eye infection
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
4 |
2 |
Eye infection bacterial
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Eyelid infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Flavivirus infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
5 / 3576 (0.14%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
5 |
0 |
Folliculitis
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
5 / 3576 (0.14%) |
7 / 3581 (0.20%) |
occurrences all number
|
5 |
4 |
5 |
8 |
Fungal infection
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
3 |
2 |
Fungal skin infection
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
9 / 3581 (0.25%) |
18 / 3576 (0.50%) |
13 / 3581 (0.36%) |
occurrences all number
|
10 |
9 |
18 |
13 |
Furuncle
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
4 / 3581 (0.11%) |
12 / 3576 (0.34%) |
7 / 3581 (0.20%) |
occurrences all number
|
8 |
4 |
13 |
7 |
Gastric infection
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Gastric ulcer helicobacter
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Gastritis viral
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Gastroenteritis
|
|
|
|
|
subjects affected / exposed
|
57 / 3576 (1.59%) |
49 / 3581 (1.37%) |
83 / 3576 (2.32%) |
99 / 3581 (2.76%) |
occurrences all number
|
62 |
53 |
93 |
107 |
Gastroenteritis bacterial
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
6 / 3581 (0.17%) |
6 / 3576 (0.17%) |
6 / 3581 (0.17%) |
occurrences all number
|
5 |
6 |
6 |
6 |
Gastroenteritis rotavirus
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Gastroenteritis viral
|
|
|
|
|
subjects affected / exposed
|
47 / 3576 (1.31%) |
43 / 3581 (1.20%) |
63 / 3576 (1.76%) |
63 / 3581 (1.76%) |
occurrences all number
|
49 |
43 |
66 |
65 |
Gastrointestinal bacterial infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Gastrointestinal bacterial overgrowth
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Gastrointestinal candidiasis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Gastrointestinal infection
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
5 / 3576 (0.14%) |
6 / 3581 (0.17%) |
occurrences all number
|
4 |
3 |
5 |
6 |
Gastrointestinal viral infection
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
6 / 3576 (0.17%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
3 |
6 |
4 |
Genital herpes
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
occurrences all number
|
3 |
5 |
10 |
6 |
Genital infection fungal
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Giardiasis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
3 |
2 |
3 |
Gingival abscess
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
0 / 3581 (0.00%) |
6 / 3576 (0.17%) |
0 / 3581 (0.00%) |
occurrences all number
|
5 |
0 |
6 |
0 |
Gingivitis
|
|
|
|
|
subjects affected / exposed
|
22 / 3576 (0.62%) |
32 / 3581 (0.89%) |
26 / 3576 (0.73%) |
38 / 3581 (1.06%) |
occurrences all number
|
22 |
32 |
28 |
38 |
Groin abscess
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Haemophilus infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Helicobacter gastritis
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
9 / 3581 (0.25%) |
occurrences all number
|
6 |
4 |
10 |
9 |
Helicobacter infection
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
11 / 3581 (0.31%) |
26 / 3576 (0.73%) |
22 / 3581 (0.61%) |
occurrences all number
|
10 |
11 |
26 |
22 |
Helminthic infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
2 |
0 |
3 |
Hepatitis B
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hepatitis C
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
3 |
0 |
Hepatitis viral
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
1 |
1 |
Herpes dermatitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
1 |
1 |
Herpes ophthalmic
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Herpes simplex
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
6 / 3581 (0.17%) |
5 / 3576 (0.14%) |
6 / 3581 (0.17%) |
occurrences all number
|
5 |
6 |
10 |
6 |
Herpes virus infection
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
occurrences all number
|
4 |
3 |
6 |
5 |
Herpes zoster
|
|
|
|
|
subjects affected / exposed
|
22 / 3576 (0.62%) |
33 / 3581 (0.92%) |
61 / 3576 (1.71%) |
72 / 3581 (2.01%) |
occurrences all number
|
24 |
33 |
63 |
73 |
Herpes zoster infection neurological
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Herpes zoster oticus
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Hookworm infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Hordeolum
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
11 / 3576 (0.31%) |
4 / 3581 (0.11%) |
occurrences all number
|
6 |
2 |
11 |
4 |
Impetigo
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Incision site infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Infected bite
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
3 |
2 |
Infected cyst
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Infected dermal cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Infected skin ulcer
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
1 |
2 |
Infection
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
2 |
3 |
Infection parasitic
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
2 |
1 |
4 |
Infective exacerbation of bronchiectasis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Infective exacerbation of chronic obstructive airways disease
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
2 |
1 |
Influenza
|
|
|
|
|
subjects affected / exposed
|
180 / 3576 (5.03%) |
169 / 3581 (4.72%) |
240 / 3576 (6.71%) |
237 / 3581 (6.62%) |
occurrences all number
|
221 |
207 |
306 |
292 |
Injection site infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Kaposi's varicelliform eruption
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Keratitis viral
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Labyrinthitis
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
7 / 3581 (0.20%) |
21 / 3576 (0.59%) |
16 / 3581 (0.45%) |
occurrences all number
|
13 |
7 |
25 |
19 |
Laryngitis
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
16 / 3581 (0.45%) |
18 / 3576 (0.50%) |
29 / 3581 (0.81%) |
occurrences all number
|
14 |
17 |
23 |
32 |
Laryngitis bacterial
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Laryngitis viral
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
occurrences all number
|
6 |
2 |
6 |
2 |
Latent syphilis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Localised infection
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
7 / 3581 (0.20%) |
occurrences all number
|
8 |
4 |
9 |
7 |
Lower respiratory tract infection
|
|
|
|
|
subjects affected / exposed
|
18 / 3576 (0.50%) |
18 / 3581 (0.50%) |
36 / 3576 (1.01%) |
31 / 3581 (0.87%) |
occurrences all number
|
22 |
18 |
55 |
40 |
Lower respiratory tract infection bacterial
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
4 |
5 |
5 |
5 |
Lower respiratory tract infection viral
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Lung infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
5 / 3581 (0.14%) |
occurrences all number
|
0 |
4 |
3 |
6 |
Lyme disease
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
occurrences all number
|
4 |
1 |
6 |
2 |
Malaria
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Mastitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Mastitis bacterial
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Mastoiditis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
1 |
1 |
Mumps
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Mycobacterial infection
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Mycobacterium avium complex infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Myringitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Nail bed infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Nail bed infection bacterial
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Nail infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Nasal abscess
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Nasopharyngitis
|
|
|
|
|
subjects affected / exposed
|
439 / 3576 (12.28%) |
460 / 3581 (12.85%) |
622 / 3576 (17.39%) |
651 / 3581 (18.18%) |
occurrences all number
|
545 |
570 |
936 |
921 |
Nematodiasis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Oesophageal candidiasis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Onychomycosis
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
16 / 3581 (0.45%) |
21 / 3576 (0.59%) |
26 / 3581 (0.73%) |
occurrences all number
|
10 |
16 |
22 |
28 |
Oral bacterial infection
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
0 |
1 |
1 |
Oral candidiasis
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
6 / 3581 (0.17%) |
9 / 3576 (0.25%) |
12 / 3581 (0.34%) |
occurrences all number
|
5 |
6 |
11 |
13 |
Oral fungal infection
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
6 / 3576 (0.17%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
1 |
6 |
2 |
Oral herpes
|
|
|
|
|
subjects affected / exposed
|
17 / 3576 (0.48%) |
22 / 3581 (0.61%) |
22 / 3576 (0.62%) |
31 / 3581 (0.87%) |
occurrences all number
|
18 |
22 |
23 |
32 |
Oral infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Oral viral infection
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
2 |
1 |
Oropharyngeal candidiasis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Osteomyelitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Osteomyelitis chronic
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Otitis externa
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
9 / 3581 (0.25%) |
6 / 3576 (0.17%) |
11 / 3581 (0.31%) |
occurrences all number
|
1 |
10 |
6 |
12 |
Otitis externa bacterial
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
2 |
0 |
2 |
Otitis media
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
5 / 3581 (0.14%) |
8 / 3576 (0.22%) |
8 / 3581 (0.22%) |
occurrences all number
|
3 |
5 |
8 |
9 |
Otitis media acute
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
5 / 3581 (0.14%) |
7 / 3576 (0.20%) |
8 / 3581 (0.22%) |
occurrences all number
|
4 |
5 |
8 |
8 |
Otitis media bacterial
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
3 |
2 |
4 |
2 |
Otitis media chronic
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Otosalpingitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Parasitic gastroenteritis
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
2 / 3581 (0.06%) |
10 / 3576 (0.28%) |
3 / 3581 (0.08%) |
occurrences all number
|
7 |
2 |
10 |
3 |
Paronychia
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
4 / 3581 (0.11%) |
8 / 3576 (0.22%) |
9 / 3581 (0.25%) |
occurrences all number
|
8 |
4 |
10 |
9 |
Parotitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
1 |
1 |
4 |
1 |
Pelvic inflammatory disease
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Peptic ulcer helicobacter
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Perichondritis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Pericoronitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Periodontitis
|
|
|
|
|
subjects affected / exposed
|
31 / 3576 (0.87%) |
20 / 3581 (0.56%) |
47 / 3576 (1.31%) |
37 / 3581 (1.03%) |
occurrences all number
|
33 |
23 |
50 |
40 |
Periorbital cellulitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Peritonsillar abscess
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
1 |
2 |
Pharyngitis
|
|
|
|
|
subjects affected / exposed
|
31 / 3576 (0.87%) |
36 / 3581 (1.01%) |
61 / 3576 (1.71%) |
69 / 3581 (1.93%) |
occurrences all number
|
36 |
39 |
72 |
77 |
Pharyngitis bacterial
|
|
|
|
|
subjects affected / exposed
|
9 / 3576 (0.25%) |
7 / 3581 (0.20%) |
10 / 3576 (0.28%) |
13 / 3581 (0.36%) |
occurrences all number
|
9 |
8 |
10 |
14 |
Pharyngitis streptococcal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Pharyngotonsillitis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
2 |
3 |
3 |
Pilonidal cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Pneumonia
|
|
|
|
|
subjects affected / exposed
|
36 / 3576 (1.01%) |
35 / 3581 (0.98%) |
64 / 3576 (1.79%) |
64 / 3581 (1.79%) |
occurrences all number
|
38 |
35 |
81 |
72 |
Pneumonia adenoviral
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Pneumonia bacterial
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
6 / 3581 (0.17%) |
13 / 3576 (0.36%) |
8 / 3581 (0.22%) |
occurrences all number
|
11 |
6 |
15 |
8 |
Pneumonia cryptococcal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Pneumonia mycoplasmal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Pneumonia viral
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Post procedural infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
3 |
1 |
Post viral fatigue syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Postoperative wound infection
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
4 / 3576 (0.11%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
5 |
2 |
Pulmonary tuberculosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Pulpitis dental
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
7 / 3581 (0.20%) |
14 / 3576 (0.39%) |
11 / 3581 (0.31%) |
occurrences all number
|
14 |
7 |
17 |
12 |
Pyelonephritis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
0 |
1 |
3 |
Pyelonephritis acute
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Pyelonephritis chronic
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Pyuria
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Rash pustular
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
2 |
1 |
3 |
Respiratory tract infection
|
|
|
|
|
subjects affected / exposed
|
13 / 3576 (0.36%) |
19 / 3581 (0.53%) |
34 / 3576 (0.95%) |
39 / 3581 (1.09%) |
occurrences all number
|
15 |
19 |
39 |
41 |
Respiratory tract infection bacterial
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
5 / 3581 (0.14%) |
6 / 3576 (0.17%) |
6 / 3581 (0.17%) |
occurrences all number
|
5 |
5 |
6 |
6 |
Respiratory tract infection viral
|
|
|
|
|
subjects affected / exposed
|
23 / 3576 (0.64%) |
10 / 3581 (0.28%) |
29 / 3576 (0.81%) |
10 / 3581 (0.28%) |
occurrences all number
|
28 |
12 |
38 |
12 |
Rhinitis
|
|
|
|
|
subjects affected / exposed
|
35 / 3576 (0.98%) |
38 / 3581 (1.06%) |
56 / 3576 (1.57%) |
59 / 3581 (1.65%) |
occurrences all number
|
37 |
39 |
59 |
66 |
Root canal infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Rotavirus infection
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Sialoadenitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Sinobronchitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Sinusitis
|
|
|
|
|
subjects affected / exposed
|
27 / 3576 (0.76%) |
51 / 3581 (1.42%) |
55 / 3576 (1.54%) |
80 / 3581 (2.23%) |
occurrences all number
|
28 |
54 |
62 |
88 |
Sinusitis bacterial
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
3 / 3581 (0.08%) |
7 / 3576 (0.20%) |
5 / 3581 (0.14%) |
occurrences all number
|
6 |
3 |
8 |
5 |
Skin bacterial infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Skin candida
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Skin infection
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
5 / 3576 (0.14%) |
5 / 3581 (0.14%) |
occurrences all number
|
1 |
4 |
5 |
5 |
Soft tissue infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
2 |
1 |
Staphylococcal infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
1 |
0 |
2 |
Staphylococcal skin infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Stoma site abscess
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Streptococcal infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Streptococcal urinary tract infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Subcutaneous abscess
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
5 / 3576 (0.14%) |
7 / 3581 (0.20%) |
occurrences all number
|
1 |
4 |
5 |
8 |
Superinfection
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Superinfection bacterial
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Tick-borne viral encephalitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
2 |
0 |
2 |
0 |
Tinea capitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Tinea cruris
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Tinea infection
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
2 / 3576 (0.06%) |
6 / 3581 (0.17%) |
occurrences all number
|
2 |
3 |
2 |
6 |
Tinea pedis
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
3 / 3581 (0.08%) |
13 / 3576 (0.36%) |
5 / 3581 (0.14%) |
occurrences all number
|
4 |
3 |
13 |
5 |
Tinea versicolour
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Tonsillitis
|
|
|
|
|
subjects affected / exposed
|
14 / 3576 (0.39%) |
18 / 3581 (0.50%) |
22 / 3576 (0.62%) |
22 / 3581 (0.61%) |
occurrences all number
|
15 |
18 |
25 |
22 |
Tonsillitis bacterial
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
6 / 3581 (0.17%) |
5 / 3576 (0.14%) |
9 / 3581 (0.25%) |
occurrences all number
|
5 |
6 |
5 |
9 |
Tooth abscess
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
13 / 3581 (0.36%) |
22 / 3576 (0.62%) |
25 / 3581 (0.70%) |
occurrences all number
|
12 |
13 |
23 |
26 |
Tooth infection
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
12 / 3581 (0.34%) |
17 / 3576 (0.48%) |
22 / 3581 (0.61%) |
occurrences all number
|
10 |
12 |
20 |
24 |
Tracheitis
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
1 |
3 |
4 |
Tracheobronchitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
2 |
2 |
Trichuriasis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Tuberculosis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Upper respiratory tract infection
|
|
|
|
|
subjects affected / exposed
|
172 / 3576 (4.81%) |
161 / 3581 (4.50%) |
255 / 3576 (7.13%) |
236 / 3581 (6.59%) |
occurrences all number
|
254 |
232 |
453 |
414 |
Upper respiratory tract infection bacterial
|
|
|
|
|
subjects affected / exposed
|
15 / 3576 (0.42%) |
19 / 3581 (0.53%) |
21 / 3576 (0.59%) |
20 / 3581 (0.56%) |
occurrences all number
|
16 |
20 |
22 |
21 |
Urethritis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Urinary tract infection
|
|
|
|
|
subjects affected / exposed
|
142 / 3576 (3.97%) |
130 / 3581 (3.63%) |
263 / 3576 (7.35%) |
244 / 3581 (6.81%) |
occurrences all number
|
156 |
147 |
331 |
296 |
Urinary tract infection bacterial
|
|
|
|
|
subjects affected / exposed
|
41 / 3576 (1.15%) |
23 / 3581 (0.64%) |
43 / 3576 (1.20%) |
28 / 3581 (0.78%) |
occurrences all number
|
44 |
26 |
47 |
34 |
Urinary tract infection enterococcal
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Urinary tract infection staphylococcal
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Urinary tract infection viral
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Vaginal cellulitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Vaginal infection
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
9 / 3576 (0.25%) |
6 / 3581 (0.17%) |
occurrences all number
|
4 |
4 |
11 |
6 |
Vaginitis bacterial
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
0 / 3576 (0.00%) |
5 / 3581 (0.14%) |
occurrences all number
|
0 |
3 |
0 |
5 |
Varicella
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Viraemia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
4 / 3581 (0.11%) |
occurrences all number
|
1 |
2 |
2 |
4 |
Viral diarrhoea
|
|
|
|
|
subjects affected / exposed
|
32 / 3576 (0.89%) |
27 / 3581 (0.75%) |
34 / 3576 (0.95%) |
27 / 3581 (0.75%) |
occurrences all number
|
34 |
28 |
36 |
28 |
Viral hepatitis carrier
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Viral infection
|
|
|
|
|
subjects affected / exposed
|
29 / 3576 (0.81%) |
30 / 3581 (0.84%) |
45 / 3576 (1.26%) |
50 / 3581 (1.40%) |
occurrences all number
|
30 |
32 |
47 |
53 |
Viral labyrinthitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
1 / 3576 (0.03%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
2 |
1 |
2 |
Viral pharyngitis
|
|
|
|
|
subjects affected / exposed
|
15 / 3576 (0.42%) |
12 / 3581 (0.34%) |
17 / 3576 (0.48%) |
13 / 3581 (0.36%) |
occurrences all number
|
18 |
12 |
20 |
13 |
Viral rash
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Viral rhinitis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
3 |
1 |
3 |
Viral sinusitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Viral skin infection
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Viral upper respiratory tract infection
|
|
|
|
|
subjects affected / exposed
|
227 / 3576 (6.35%) |
206 / 3581 (5.75%) |
263 / 3576 (7.35%) |
230 / 3581 (6.42%) |
occurrences all number
|
312 |
283 |
394 |
352 |
Vulvovaginal candidiasis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
1 |
3 |
2 |
Vulvovaginal mycotic infection
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
8 / 3576 (0.22%) |
3 / 3581 (0.08%) |
occurrences all number
|
6 |
4 |
9 |
5 |
Vulvovaginitis
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Wound infection
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
2 / 3581 (0.06%) |
8 / 3576 (0.22%) |
9 / 3581 (0.25%) |
occurrences all number
|
6 |
2 |
9 |
9 |
Wound infection bacterial
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Zika virus infection
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
3 |
1 |
Metabolism and nutrition disorders
|
|
|
|
|
Abnormal loss of weight
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
1 |
3 |
Acquired mixed hyperlipidaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Cachexia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
2 |
0 |
4 |
Calcium metabolism disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Carbohydrate intolerance
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
7 / 3581 (0.20%) |
8 / 3576 (0.22%) |
14 / 3581 (0.39%) |
occurrences all number
|
5 |
7 |
8 |
14 |
Central obesity
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Cow's milk intolerance
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Decreased appetite
|
|
|
|
|
subjects affected / exposed
|
32 / 3576 (0.89%) |
24 / 3581 (0.67%) |
48 / 3576 (1.34%) |
42 / 3581 (1.17%) |
occurrences all number
|
32 |
24 |
48 |
44 |
Dehydration
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
3 / 3576 (0.08%) |
4 / 3581 (0.11%) |
occurrences all number
|
2 |
2 |
4 |
4 |
Diabetes mellitus
|
|
|
|
|
subjects affected / exposed
|
31 / 3576 (0.87%) |
34 / 3581 (0.95%) |
61 / 3576 (1.71%) |
57 / 3581 (1.59%) |
occurrences all number
|
31 |
35 |
64 |
63 |
Diabetes mellitus inadequate control
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
7 / 3581 (0.20%) |
12 / 3576 (0.34%) |
13 / 3581 (0.36%) |
occurrences all number
|
7 |
7 |
13 |
14 |
Diabetic metabolic decompensation
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Dyslipidaemia
|
|
|
|
|
subjects affected / exposed
|
74 / 3576 (2.07%) |
81 / 3581 (2.26%) |
137 / 3576 (3.83%) |
134 / 3581 (3.74%) |
occurrences all number
|
74 |
81 |
143 |
136 |
Electrolyte imbalance
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
5 / 3576 (0.14%) |
5 / 3581 (0.14%) |
occurrences all number
|
2 |
0 |
5 |
5 |
Fluid overload
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Fluid retention
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
1 |
2 |
2 |
Folate deficiency
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
1 |
0 |
2 |
2 |
Food intolerance
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Glucose tolerance impaired
|
|
|
|
|
subjects affected / exposed
|
12 / 3576 (0.34%) |
16 / 3581 (0.45%) |
24 / 3576 (0.67%) |
27 / 3581 (0.75%) |
occurrences all number
|
12 |
16 |
25 |
27 |
Gout
|
|
|
|
|
subjects affected / exposed
|
7 / 3576 (0.20%) |
3 / 3581 (0.08%) |
14 / 3576 (0.39%) |
5 / 3581 (0.14%) |
occurrences all number
|
12 |
3 |
19 |
7 |
Hyper HDL cholesterolaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
2 |
0 |
Hyperammonaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hypercalcaemia
|
|
|
|
|
subjects affected / exposed
|
5 / 3576 (0.14%) |
1 / 3581 (0.03%) |
19 / 3576 (0.53%) |
8 / 3581 (0.22%) |
occurrences all number
|
5 |
1 |
20 |
8 |
Hyperchloraemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Hypercholesterolaemia
|
|
|
|
|
subjects affected / exposed
|
42 / 3576 (1.17%) |
45 / 3581 (1.26%) |
72 / 3576 (2.01%) |
85 / 3581 (2.37%) |
occurrences all number
|
42 |
45 |
74 |
87 |
Hyperglycaemia
|
|
|
|
|
subjects affected / exposed
|
24 / 3576 (0.67%) |
27 / 3581 (0.75%) |
41 / 3576 (1.15%) |
50 / 3581 (1.40%) |
occurrences all number
|
26 |
28 |
48 |
56 |
Hyperkalaemia
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
9 / 3581 (0.25%) |
18 / 3576 (0.50%) |
14 / 3581 (0.39%) |
occurrences all number
|
11 |
9 |
18 |
14 |
Hyperlipidaemia
|
|
|
|
|
subjects affected / exposed
|
21 / 3576 (0.59%) |
12 / 3581 (0.34%) |
31 / 3576 (0.87%) |
26 / 3581 (0.73%) |
occurrences all number
|
21 |
12 |
31 |
26 |
Hypermagnesaemia
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
1 / 3581 (0.03%) |
7 / 3576 (0.20%) |
3 / 3581 (0.08%) |
occurrences all number
|
4 |
1 |
8 |
4 |
Hypernatraemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
0 / 3576 (0.00%) |
4 / 3581 (0.11%) |
occurrences all number
|
0 |
2 |
0 |
4 |
Hyperproteinaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hypertriglyceridaemia
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
17 / 3581 (0.47%) |
13 / 3576 (0.36%) |
22 / 3581 (0.61%) |
occurrences all number
|
6 |
17 |
13 |
22 |
Hyperuricaemia
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
10 / 3581 (0.28%) |
14 / 3576 (0.39%) |
18 / 3581 (0.50%) |
occurrences all number
|
8 |
10 |
14 |
19 |
Hypervitaminosis
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Hypoalbuminaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
2 / 3581 (0.06%) |
occurrences all number
|
0 |
0 |
0 |
2 |
Hypocalcaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
8 / 3581 (0.22%) |
occurrences all number
|
0 |
1 |
3 |
8 |
Hypochloraemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
2 |
1 |
Hypoglycaemia
|
|
|
|
|
subjects affected / exposed
|
8 / 3576 (0.22%) |
11 / 3581 (0.31%) |
12 / 3576 (0.34%) |
19 / 3581 (0.53%) |
occurrences all number
|
8 |
13 |
13 |
24 |
Hypokalaemia
|
|
|
|
|
subjects affected / exposed
|
10 / 3576 (0.28%) |
15 / 3581 (0.42%) |
24 / 3576 (0.67%) |
28 / 3581 (0.78%) |
occurrences all number
|
10 |
15 |
24 |
31 |
Hypomagnesaemia
|
|
|
|
|
subjects affected / exposed
|
3 / 3576 (0.08%) |
0 / 3581 (0.00%) |
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
occurrences all number
|
3 |
0 |
4 |
4 |
Hyponatraemia
|
|
|
|
|
subjects affected / exposed
|
6 / 3576 (0.17%) |
10 / 3581 (0.28%) |
17 / 3576 (0.48%) |
24 / 3581 (0.67%) |
occurrences all number
|
7 |
10 |
19 |
27 |
Hypophosphataemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
2 |
0 |
Hypoproteinaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Hypovolaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Impaired fasting glucose
|
|
|
|
|
subjects affected / exposed
|
11 / 3576 (0.31%) |
10 / 3581 (0.28%) |
14 / 3576 (0.39%) |
15 / 3581 (0.42%) |
occurrences all number
|
11 |
10 |
14 |
15 |
Increased appetite
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
1 / 3581 (0.03%) |
occurrences all number
|
2 |
1 |
3 |
1 |
Insulin resistance
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Iron deficiency
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
1 |
2 |
3 |
Lactose intolerance
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Latent tetany
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Lipid metabolism disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
1 / 3581 (0.03%) |
3 / 3576 (0.08%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
1 |
4 |
3 |
Malnutrition
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
3 / 3581 (0.08%) |
occurrences all number
|
0 |
0 |
1 |
4 |
Metabolic disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Metabolic syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
1 |
0 |
1 |
0 |
Obesity
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
0 / 3581 (0.00%) |
6 / 3576 (0.17%) |
3 / 3581 (0.08%) |
occurrences all number
|
2 |
0 |
6 |
3 |
Overweight
|
|
|
|
|
subjects affected / exposed
|
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
2 / 3576 (0.06%) |
2 / 3581 (0.06%) |
occurrences all number
|
2 |
2 |
2 |
2 |
Periarthritis calcarea
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Plasma protein metabolism disorder
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
0 |
0 |
1 |
Polydipsia
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
0 / 3576 (0.00%) |
1 / 3581 (0.03%) |
occurrences all number
|
0 |
1 |
0 |
1 |
Type 2 diabetes mellitus
|
|
|
|
|
subjects affected / exposed
|
17 / 3576 (0.48%) |
21 / 3581 (0.59%) |
35 / 3576 (0.98%) |
34 / 3581 (0.95%) |
occurrences all number
|
17 |
22 |
36 |
37 |
Underweight
|
|
|
|
|
subjects affected / exposed
|
0 / 3576 (0.00%) |
0 / 3581 (0.00%) |
1 / 3576 (0.03%) |
0 / 3581 (0.00%) |
occurrences all number
|
0 |
0 |
1 |
0 |
Vitamin B complex deficiency
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
1 / 3581 (0.03%) |
2 / 3576 (0.06%) |
3 / 3581 (0.08%) |
occurrences all number
|
1 |
1 |
2 |
3 |
Vitamin B12 deficiency
|
|
|
|
|
subjects affected / exposed
|
4 / 3576 (0.11%) |
4 / 3581 (0.11%) |
8 / 3576 (0.22%) |
11 / 3581 (0.31%) |
occurrences all number
|
4 |
4 |
9 |
11 |
Vitamin D deficiency
|
|
|
|
|
subjects affected / exposed
|
1 / 3576 (0.03%) |
4 / 3581 (0.11%) |
6 / 3576 (0.17%) |
12 / 3581 (0.34%) |
occurrences all number
|
1 |
4 |
6 |
12 |